



españa, **technology for life.**



asebio report 2008





Executive Summary 2008





Edited by Spanish Association of Bioenterprises (ASEBIO)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopies, recordings or any information storage and retrieval, without written permission from the copyright holders.

© ASEBIO

1st edition: June 2009

Design: Margen

Photocomposition and impression: Gráficas Enar, S.A.

Legal deposit:

EXECUTIVE SUMMARY 2008

Executive Summary:

1. The Situation of the Spanish Biotechnology Sector	6
2. New enterprises created in 2008	10
3. Business activities undertaken	13
4. Industrial Property and Knowledge Generation	23
5. Red Biotechnology	49
6. Green Biotechnology	50
7. White Biotechnology	50
8. The Finance Environment	51
9. Internationalisation	55

Appendix: 1 Who is who? - ASEBIO Members	65
--	----





asebio



Executive Summary





1. THE SITUATION OF THE SPANISH BIOTECHNOLOGY SECTOR

Companies with biotech activity

According to the latest National Statistics Bureau (Spanish initials INE) Survey on Technological Innovation in Companies, the number of enterprises making use of biotechnology in Spain came to 764, while the number of those companies considered strictly biotech was up 22% year-on-year to stand at 257.

Sector turnover reached €26,150 million and it employed 103,911 in 2007. The year-on-year increases for the two variables stood at 16% and 18% respectively. Internal spending on R&D in activities to do with biotechnology undertaken by these companies continued to rise, up 27.6% year-on-year.

Graph 1:
Evolution of the
number of compa-
nies with activities
in biotechnology.



Table 1.

Main outcomes from the biotechnology module in the Survey on Technological Innovation in Companies 2007

Main Variables	Under 250 employees	Over 250 employees	Total 2007	Total 2006	Difference	Growth Rate
Companies using biotechnology	691	73	764	659	105	15.9%
Companies in which biotechnology is one of the main and/or exclusive activity	238	19	257	211	46	21.8%
Companies in which biotechnology is a secondary business line	163	16	179	159	20	12.6%
Companies in which biotechnology is a necessary tool for production	290	38	328	289	39	13.5%
Companies undertaking R&D activities in biotechnology	506	55	561	467	94	20.1%
Total Employment	25,125	78,786	103,911	88,124	15,787	17.9%
Turnover (€Thousands)	5,448,127	20,701,727	26,149,854	22,549,792	3,601,062	16.0%
R&D staff in biotechnology (No. people)	3,873	1,355	5,228	4,448	780	17.5%
A) Total by post						
Researchers	2,136	810	2,946	2,449	497	20.3%
Technicians and auxiliaries	1,737	545	2,282	1,999	283	14.2%
Private Internal R&D spending on biotechnology (€ Thousands)	253,334	122,812	376,146	294,845	81,301	27.6%
B) By source of funds						
Domestic Funds	245,323	87,084	332,407	273,380	59,027	21.6%
• Own funds	141,711	73,381	215,092	180,832	34,260	18.9%
• From companies	21,034	4,603	25,637	24,172	1,465	6.1%
• From the Public Administration	80,270	8,543	88,813	65,448	23,365	35.7%
• From Universities	290	0	290	250	40	16.0%
• From private, not-for-profit institutions	2,018	558	2,576	2,678	-102	-3.8%
Funds coming from abroad	8,011	35,728	43,739	21,465	22,274	103.8%
• From European Union programmes	4,784	1,720	6,504	4,283	2,221	51.9%
• Other funds coming from abroad	3,227	34,008	37,235	17,182	20,053	116.7%



Executive Summary

As in the previous year, the variable experiencing the highest growth was investment in R&D in biotechnology undertaken by companies with activities in biotechnology in national territory (internal spending on R&D in biotechnology). With a year-on-year increase of 27.6%, it came to €376.15 million. Given the emerging nature of the sector, this variable is expected to continue to rise at similar rates in the years to come.

Total internal spending on R&D in biotechnology reached €1,123 million in 2007, versus the €931million reported the previous year. As is seen in other sectors, the attraction of international funds is an item susceptible to improvement, given that funds from this source accounted for only 7.5% of the total.


The percentage spread of how companies with biotech activities apply these remained virtually unchanged with respect to the previous year.



Graph 2:

Percentage of companies according to the area in which biotechnology is eventually used.

Source: Spanish National Statistics Bureau, Survey on Technological Innovation in Companies, 2007



Strictly biotech companies (biotechs)


According to the National Statistics Bureau, the total number of companies whose main and/or exclusive activity in 2007 was biotechnology stood at 257, versus the 211 reported the previous year. Almost 93% of the national biotechs are companies with fewer than 250 employees.

Furthermore, 179 companies declared that biotechnology was a secondary business line; while 328 classified it as a necessary tool for production.

Graph 3:

Geographical spread of the biotechs

Source: Spanish National Statistics Bureau, Survey on Technological Innovation in Companies, 2007





2. NEW ENTERPRISES CREATED IN 2008

In collaboration with the bio-regions, ASEBIO detected a total of 40 biotech companies that started up activities during 2008, with Catalonia and Andalusia being the most enterprising autonomous communities in the creation of new business projects, these territories respectively accounting for 25% and 18% of the total.

Table 2.

Companies created during 2008

Name	Activity	Aut. Communities
Abro Biotec	Development, production, marketing and sale of natural extracts for the food, pharmaceutical, cosmetics industries, etc.	Castilla-León
Alergénica	Biotech survey and analysis services of proteins for improving human life, allergies, fungi and making vaccines.	Canary Islands
ALGASOL RENEWABLES	Biodiesel production using oil-giving algae, other micro-organisms and CO ₂	Balearic Islands
AMSLab	A laboratory specialising in the use of mass spectrometry coupled to liquid chromatography.	Galicia
Bacterialia	A food microbiology laboratory. Analysis and consultancy in HACCP systems.	Catalonia
BCNINNOVA Technological Evolution	Research and marketing of clean energy generation apparatus and of electro-medical and orthopaedic equipment for professional and scientific use.	Catalonia

BINOT ASOCIADOS SL	Scientific and technical research. Performance of all kinds of agrifood and biotech projects and surveys.	Balearic Islands
Biodatec	Research, development, production and distribution of new ingredients.	La Rioja
BIOFUNGITEK	Biotech research and development in the sphere of biopesticides.	Basque Country
BIOTECNOLOGÍA DE MICROALGAS, SL	Industrial production of micro-algae that use the CO2 issued to produce different sub-products: Algae oil, food products (Proteins, Fatty Acids including Omega 3, Carotenoids and pigments), Cosmetics and Pharmaceutical Products.	Andalusia
BRAIN DYNAMICS, SL	Development of neuroscience software.	Andalusia
Brainco	The development of personalised treatments of diseases of the human central nervous system and medicines directed against new therapeutic targets and microchips for individual response diagnostics, prognosis and prediction to the pharmacological treatment.	Basque Country
Catfosc	R&D projects and health education. Medical technology, products and instruments.	Catalonia
Celartia Europe	The development of new technologies for cell cultures and functional assessment of cells.	Valencia
Chronobiotech	Chronobiology and circadian consultancy.	Murcia
Cleaanlgae	Cultivation of edible algae and their application in animal feed.	Canary Islands
CRONOFARMA, S.L.L.	Research and development of medicinal drugs.	Andalusia
Dawnesh Radiation Research Institute	Studies on the effect of radiation on cell structures.	Catalonia
DEINAAL SOLUCIONES AGROALIMENTARIAS, S.L.	R&D activities in the field of food technology, food safety and nutrition.	Galicia
DELTANEK	The development of technologies for treating organic waste.	Basque Country
Felix Fernández Martín	Mycorrhizal bio-fertilizers for the agricultural, forestry and gardening worlds.	Murcia
FELNUTI	The development, manufacturing, marketing, import and distribution of food products and products specifically for consumers who suffer from intolerance or allergies to certain foods.	Catalonia
Geniality	Genetic diagnostics devoted to reproductive genetics.	Madrid



GESMAT 8 EXERCITIA	Sale, rental, distribution and research of materials and machinery for Medicine, Dentistry, Pharmacology and Cosmetics. Medical technology, products and instruments.	Catalonia
Gladiolus Breeder's Group	Obtainment, multiplication, selection, exploitation and commercialisation of plant varieties (gladioli).	Catalonia
HONGO'S Biofactory	Mycological biotechnology.	La Rioja
Inbiogal: Innovación Biológica de Galicia	Scientific training and consultancy services in the biochemical and molecular biology spheres.	Galicia
INGREDIENTIS BIOTECH	The discovery and development of active ingredients.	Andalusia
INVITROTEK SERVICIOS DE MULTIPLICACION VEGETAL S.L.	Plant multiplication services.	Basque Country
MD Renal life science	Mass spectroscopy development for metabolic studies.	Basque Country
MedicalSoft InterCath	Specialising in research and implementation of the most advanced technologies applied to Biomedicine.	Catalonia
Mitra Solutions	Functional foods and obtainment of bioactive extracts from food industry waste.	Murcia
Neocodex REPROFILING	Drug repositioning.	Andalusia
NIMgenetics	Genetic diagnostics based on the use of high-resolution genomic systems.	Madrid
Ninsar AgroSciences	Performance and co-ordination of research projects in technologies applied to the life sciences, together with technology and knowledge management, use and capitalisation.	Catalonia
PRADOMUDO INVESTIGACIÓN Y DESARROLLO, S.L.	The manufacture of pectin, limonene, narangin and hesperidin from oranges for the cosmetics and pharmaceutical industry.	Andalusia
qGenomics - Quantitative Genomic Medicine Laboratories	The development and application of products and services deriving from genomic research for the healthcare sector.	Catalonia
SCORE Biotech, S.L.,	Research and development in the biotech sphere offering testing services for materials and prostheses to be used in the human body.	Galicia
SUR ALGAE	Macro-algae production for human consumption.	Andalusia
X-Pol Biotech S.L	Bio-applications of polymerase in DNA repairs and diagnostics	Madrid



3. BUSINESS ACTIVITIES UNDERTAKEN


Partnerships

A total of 68 partnerships were reported, of which 64% took place between Spanish entities. Of these agreements, 22% occurred with companies belonging to the European Union and 61% with Spanish companies.

Graph 4:

Spread of the partnerships in the Spanish biotechnology sector in 2008 according to partner origin.

Source: ASEBIO.





This year there was an increase in the agreements with public entities, accounting for 46% of the total number of partnerships, which was a considerable increase over the previous year (22%) and one of the sector's most highly valued priorities. 35% of the partnerships were with other biotech companies and 19% with user companies.

Graph 5:
Spread of the partnerships in the Spanish biotechnology sector in 2008 according to partner profile.
Source: ASEBIO.




Table 3:
Partnerships and collaboration agreements .
Source: ASEBIO

Companies	Objective
Advancell (SP)/Fundación la Fe (SP)	Bioanalysis and Metabolomics Unit
SIGMA-ALDRICH (SP) / ATLAS ANTIBODIES AB (SP)	Distribution of Prestige Antibodies TM developed by the Human Proteome Resource (HPR).
NEOCODEX (SP)) / Region of Murcia Autonomous Community (SP) / ALZHEIMER FOUNDATION (SP)	Development of diagnostic and therapeutic tools applicable to common neurological diseases.
Biomedal (SP) / University of Stanford (USA)	Preclinical and clinical trials using the Glutentox® analytical system.
Parc Científic de Barcelona (SP) / Uni- versity of Barcelona (SP) / Bank of Santander (SP)	Programme for boosting the transfer of results from innovative research projects.
NorayBio (SP) / Cultek Group(SP)	Exclusive marketing of the NorayBio catalogue in Spain and Portugal.



NATRACEUTICAL GROUP (SP) / BÜHLER (CH)	Collaboration for the development of an exclusive ingredient derived from cocoa.
Noraybanks (SP)/ VIRGEN DE LAS NIEVES TEACHING HOSPITAL GRANADA (SP)	Collaboration for the management of the Tumour Bank with the NorayBanks IT Platform.
PROTEOMIKA (SP) / Auguron Biosciences, Inc (USA)	Exclusive access to use NAPPA technology for research on a biomarker.
Innofood I+D+I S.L. (SP) / Importaco (SP)	Exploitation of sub-products.
Cartif Foundation (SP) / Castilla y León Regional Authorities (SP)	Creation of a Green Biotechnology cluster.
ORYZON (SP) / CRYSTAX (SP)	An agreement to boost pharmaceutical lines for the treatment of various types of cancer and neurodegenerative diseases.
Araclon Biotech (SP) / La Rioja Regional Government (SP)	Collaboration for the development of a prediction kit for Alzheimer's disease.
Calantia Biotech (SP) / BASF Plant Science	An agreement for exploiting patents for raising crop yield.
Biotoools (SP) / DIA.PRO (IT)	LIONPROBES® technology licence; a system for detecting nucleic acids in real time.
HISTOCELL (SP) / SALVAT (SP)	Development of a new medicinal drug in cell therapy for bone regeneration.
Parc Científic de Barcelona (SP) / Univer- sity Technology Park (USA)	Convention for fostering research and knowledge transfer between universities and enterprises in the sphere of biotechnology.
Advancell (SP) / Various (NORSK INSTI- TUTT FOR LUFTFORSKNING as co-ordinator)	Preparation of biological markers for toxicity testing.
Merck Serono (SP) / Bionomics (SP)	Development of medicinal drugs against multiple sclerosis.
Pevesa (SP) / Natraceutical (SP)	Development of hydrolysates and peptides for functional foods.
BIONATURIS (SP) / SANIRED (SP)	Collaboration in the FLYLIFE platform.
Biobide S.L. (SP) / Pharmakine (SP)	An agreement for mutual product/services marketing.
Bosques Naturales/ Polytechnical University of Madrid (UPM) (SP)	Research in the forestry genomics area in the obtainment of geno- types resistant to environmental stress.
Biotoools (SP) / FIOCRUZ (BR)	Stabilisation technology licence and development of joint HIV-HCV molecular diagnosis systems for introduction into federal level blood banks in Brazil.
Biotoools (SP) / SPARTAN (CA)	Development of swift molecular diagnosis systems at patient points of attention.
BIOTOOLS (SP) / Madrid Autonomous University (SP)	Search, development and scaling of new enzyme activities with ap- plications in Molecular Biology.
NorayBio (SP) / Era7 (SP)	Technological collaboration



NorayBio (SP) / Pharmasafe (CH)	Agreement for marketing NorayBio software from the biopharmacy line in Switzerland and Italy.
NorayBio (SP) / Bioindustry Park Canavese (IT)	Partnership to open NorayBio's first international sales office in Italy.
HISTOCELL (SP) / SALVAT (SP)	Development of a new cell therapy drug in for bone regeneration.
HISTOCELL (SP) / QUIMERA INGENIERÍA BIOMÉDICA (SP)	Agreement for the development of new biomaterials for tissue regeneration.
BIOT (SP) / University of Granada (SP)	Development of new probiotics.
Ingenasa (SP) / Prionics (SW)	Strategic production and collaboration agreement.
Ingenasa (SP) / NARVAC (RU)	Strategic production and collaboration agreement.
Palau Pharma (SP) / Stiefel Laboratories (USA)	Licence agreement for development and marketing of albaconazol.
Palau Pharma (SP) / Schering-Plough (USA)	Licence agreement for the development and marketing of the AMP p38 kinase inhibitor.
Palau Pharma (SP) / Esteve (SP) / Almirall (SP) / Cristax (SP) / Enantia (SP) / Galchemia (SP)	CNIT Programme: Genius Pharma Project. Development and consolidation of technology platforms in order to improve the drug identification process.
Neocodex (SP)/IMPPC (SP)	GWS in cancer of the colon.
Neocodex (SP) / Virgen Macarena Hospital (SP)	GWS in multiple sclerosis.
Neocodex (SP) / National Cancer Center(JA)	GWS in lung cancer .
3P BIOPHARMACEUTICALS (SP) / CIMA (SP)	Development of an expression system in mammal cells based on the Semiliki Forest Virus (SFV).
NEURON BPh (SP) / SOS Group (SP)	Collaboration for research into new functional ingredients and development of bioprocesses.
HISTOCELL (SP)/NEURON BPh (SP)	Development of a diagnostics kit to verify the effectiveness of drugs against Alzheimer's disease.
NEURON Bph (SP)/BECTEL ENGINEERS (SP)	Collaboration Agreement for the development of Bioprocesses for the pharmaceutical, chemical, food and energy industries.
NEURON Bph (SP)/INNOFOOD I+D+i (SP)	Collaboration in technical and commercial matters.
NEURON Bph (SP)/LAIMAT (SP)	Collaboration in technical and commercial matters.
NEURON Bph (SP) / VALENTIA BIOPHARMA (SP)	Collaboration agreement for the development of animal models.
IUCT (SP) / ORTHOTOPICS (FI) / CCTI (RU)	Collaboration agreement for the development of new active anti-cancer compounds.
IUCT (SP) / COGNIS (GE)	Development of solvents obtained from renewable materials for degreasing metals and other applications.

IUCT (SP) / ALBUS GOLF (SP)	Development of a new biodegradable golf ball.
Laimat (SP) / University of Granada (SP)	Research and development of new colloidal products.
Laimat (SP) / University of Granada (SP)	Research and development of new products with biotech applications.
Laimat (SP) / Barcelona Institute of Materials Sciences (ICMAB-CSIC) (SP)	Development of biosensors to detect drugs.
SISTEMAS GENÓMICOS (SP) / Genoma España (SP)	MELONOMICS: Development of genomic tools in cucurbits, including the sequencing of the melon genome and its application for improving these crops.
SISTEMAS GENÓMICOS (SP) / Applied Biosystems	Development of new applications based on mass sequencing using the SOLiD Platform.
Sistemas Genómicos (SP) / Genoma España (SP)	OLIGEN: Development of genomic tools in olive trees for identifying the characteristics associated with their fruit and oil composition.
Biópolis S.L. (SP) / Garrigues: "Integral food consulting" (SP)	Joint technical and legal consultancy services for the food industry.
Biópolis S.L. (SP) / Novozymes (SP)	Agreement for the development of new applications for commercial enzymes and for enzymes under development.
Vivia Biotech (SP)/University of Salamanca (Cancer Research Centre) (SP)	Agreement for research into new drug indications and personalised medicine in haematological cancers.
Vivia Biotech (SP) /Fundación IMABIS (SP)	Agreement for research into new drug indications and personalised medicine in haematological cancers.
Vivia Biotech (SP) / Niño Jesús Children's Teaching Hospital (SP)	Agreement for research into new drug indications and personalised medicine in haematological cancers in children.
Coretherapix (SP) / Carlos III National Cardiovascular Research Centre Foundation (SP)	Collaboration agreement for undertaking preclinical and clinical trials of cardiac regeneration therapies.
Genetrix (SP) / Laboratory of Dr. Luis Blanco of the Severo Ochoa Molecular Biology Centre (CSIC-UAM) (SP)	Development of diagnostic and therapeutic applications of new polymerase in DNA repair and molecule diagnosis.
NEIKER (SP) / IME-Fraunhofer (GER) / Max Planck Institut für Züchtungsforschung (GER)	R&D collaboration
NEIKER (SP) / 18 institutions in Latin America belonging to 11 countries.	R&D collaboration, meetings
NEIKER (SP) / Servicio Nacional de Aprendizaje - SENA (CO)	Exchange of knowledge, technology and staff.
NEIKER (SP) / University of Panama (PA)	Scientific, academic and cultural collaboration.



Product launches onto the market

According to the survey undertaken by ASEBIO among its member companies, there were a total of 72 product and service launches in 2008, surpassing the 64 reported the previous year. As far as their spread is concerned, the Health Care area (human and animal) occupied first place, accounting for 64% of the products, followed by the Agrifood area (12%) and Industrial Processes (11%).

Most are research and development services, followed by diagnostic, research and industrial products. We should also highlight the existence of different software applications focussing on management, analysis or design of different research activities and services.



Graph 6:

Spread by sector of application of products and services launched onto the market by Spanish biotech companies in 2008.

Source: ASEBIO.




Table 4:**Product launches onto the market.** Source: ASEBIO.

Company	Product/Service Name	Type
GAIKER-IK4	Method for diagnosing miscarriages in ruminants	Diagnostics product
MERCK	New formulation of the anti-cancer drug Erbitux	Therapeutic product
INTEMAN	BIO100 BACTERFLOW	Industrial product (Biodetergent)
INTEMAN	BIO100 PROFLUID	Industrial product (Biodetergent)
INTEMAN	BIO100 PROSOLID	Industrial product (Biodetergent)
UNIVERSITY OF NAVARRE / Ingenasa	Kit for detecting the "Brucella" bacteria	Diagnostics product
MERCK SERONO	PERGOVERIS	Therapeutic product
NEURON BIOINDUSTRIAL	Platform for biotechnological evaluation of industrial sub-products	Research service
NEURON BIOPHARMA	Integrated screening platform in cell models and animals	Research service
Merck Serono	Interactive Atlas of Assisted Reproduction	Software
Noray BG	NorayLIMS software for managing and integrating research and laboratory data	Software
Genomica SAU	CLART® Entherpex platform	Research service
Sigma Life Science	ZFN CompoZr™ Technology	Research service
Biobide	CARDIOTOX ASSAY screening platform for cardiotoxicity in zebrafish	Research service
Biobide	TERATOX ASSAT teratogenesis trial in zebrafish	Research service
Biobide	OTOTOX ASSAT ototoxicity trial in zebrafish	Research service
Biobide	ACUTTOX ASSAY acute toxicity trial in zebrafish	Research service
JUSTEBIOTEC	Proscan-Juste®: DNA chip capable of analysing different SNPs associated with prostate cancer	Diagnostics product



JUSTEBIOTEC	Artchip-Juste®: DNA chip capable of analysing a variety of SNPs associated with Rheumatoid Arthritis	Diagnostics product
Advancell	Method for transporting live cells	Research service
SISTEMAS GENOMICOS	AutentiGEN®-CHIMERISM set: Real Time PCR analysis system for chimerism studies in transplant monitoring	Diagnostics product
SISTEMAS GENOMICOS	Automated FISH in spermatozoa for studying aneuploidies and segregation patterns	Research service
SISTEMAS GENOMICOS	Ocohaematological Genetics. Haematological neoplasia (diagnostics, prognosis, assessment of minimal residual disease and treatment evaluation)	Research service
SISTEMAS GENOMICOS	Mass sequencing services applied to: Directed resequencing, gene expression studies, SNP studies, whole transcriptome studies and small RNA studies, amongst others.	Research service
Lorgen	Detesex (diagnostics of sexually associated diseases)	Diagnostics product
BIONATURIS	FLYLIFE Industrial scale production of recombinant proteins in BEVs systems	Development service
BIOTOOLS	CHOLEST-CHIP® INVESTIGACIÓN Microarray of gene expression for control and supervision of lipid metabolism (research tool)	Research product/service
NorayBio	ServiLIMS software for managing general research services in universities and research centres	Software
NorayBio	BioLIMS software for integrating information produced in bioscience laboratories	Software
NorayBio	Histomass software for analysing the results of mass spectrometry experiments performed on tissues	Software
NorayBio	AniBio software for management of research centres with aquatic animals	Software
INNOFOOD	Technology for exploiting sub-products from the agrifood industry	Research service
BIOT	Probiotic bacteria with immunomodulating activity	Product

AGRASY	New functional cereal for the agrifood industry	Product
INTELLIGENT PHARMA	Helios: IT programmes for new drug design	Software
Palau Pharma / Iberhospitex	Stent ACTIVE®	Therapeutic product
Neuroscience Technologies	NT-ectopia©: Automatic quantification of axonal hyperexcitability in C nociceptors	Research and diagnostics service
Neuroscience Technologies	NT-transduction©: Assessment of C nociceptor transducer properties	Research and diagnostics service
Neuroscience Technologies	NT-mem©: Analysis of multiple metrics of axonal membrane excitability	Research and diagnostics service
FARM BIOCONTROL,S.L.	Diagnosis of the hygiene-biosanitary status in the agrifood industry	Research service
Ingredientis Biotech	Platform for the discovery of active ingredients	Research service
Ingredientis Biotech	Platform for exploiting sub-products from the agrifood industry	Research service
Era7 (Bioinformatics division)	NGS (Next Generation Sequencing) data analysis service	Bioinformatics service
Era7 (Bioinformatics division)	Genome annotation service	Bioinformatics service
Era7 (Bioinformatics division)	Expression data (transcriptome) analysis service	Bioinformatics service
Era7 (Bioinformatics division)	Cloud computing service for mass data analysis	Bioinformatics service
Era7 (Bioinformatics division)	Metagenomic data analysis service	Bioinformatics service
IUCT	New solvents obtained from renewable materials for degreasing metals	Industrial product (Biodegreasing agent)
IUCT	New library of anti-carcinogenic compounds	Product
IUCT	New library of anti-viral compounds	Product
IUCT	New Oxidase-Phosphorylase biocatalysts	Industrial product (Bioenzymes)
IUCT	New Lipase biocatalysts	Industrial product (Bioenzymes)
A&B Laboratorios de Biotecnología	Biodetergents with the European Ecolabel	Industrial product (Biodetergent)



Executive Summary

Biópolis S.L.	Screening platform for aging and obesity in the <i>Caenorhabditis elegans</i> worm	Research service
Puleva Biotech	Exxenterol: Hypcholesterolemic product	Product (Functional Food)
Puleva Biotech	Valexxol: Hypnotic sedative	Therapeutic product
Puleva Biotech	Olivia: Cardiovascular, high blood pressure and hypocholesterolemic risk	Diagnostics product
Puleva Biotech	HEREDITUM: Treatment of mastitis, Inflammatory Intestinal disease	Therapeutic product
ZF Biolabs / BIOBIDE / AZTI-Tecnalia / CABD-CSIC/ PRBB	DareNET Network [Technological Platform for boosting the application of the Zebrafish (<i>Danio rerio</i>) model]	Research service
ZF BIOLABS	ZF ACUTOX Kit, for assessing a compound's acute toxicity effect	Research product
ZF BIOLABS	ZF ACUTOX-PLUS Kit, for assessing acute toxicity and other effects of a compound to be tested	Research product
ZF BIOLABS	ZF S-CARDIAC Kit, for assessing a compound's effect on the functioning of the heart	Research product
ZF BIOLABS	ZF S-DIGESTIVE Kit, for assessing a compound's effect on the functioning of the digestive tract	Research product
ZF BIOLABS	ZF S-OMR Kit, for assessing a compound's effect on the optomotor functioning	Research product
ZF BIOLABS	ZF Basic Training Kit, designed for those researchers with no prior experience with the zebrafish model	Research product
ZF BIOLABS	ZF Embryos Kit, a set of zebrafish embryos for different uses as an alternative model animal	Research product
Biomedal	Glutentox® Competitive ELISA	Diagnostics product
Biomedal	Glutentox® Sticks	Diagnostics product
Biomedal	Anti hGSTT1 ELISA	Diagnostics product
Sensia	Biosensor based on Surface Plasmon Resonance (SPR) which enables biomolecular interactions and the presence of chemical compounds to be analysed.	Research product
X-Pol Biotech	Polymerase Kit	Research product
NEIKER	Method of detecting the Blue Tongue Virus (BTV) by RT-PCR	Diagnostics product

4. INDUSTRIAL PROPERTY AND KNOWLEDGE GENERATION

Industrial Property

In 2008, the Madrid Science Park, in collaboration with ASEBIO, identified 117 biotech inventions (both patent applications and awards) the ownership of which belongs to Spanish enterprises members of ASEBIO. In comparison to the figure reported in 2007 (84), this represents a 40% increase in the number of inventions identified.

Of these 117 inventions, which were spread among 36 entities, 79% were patent applications, the most significant being those submitted via the EPO (34%), followed by the USPTO (24%).


The majority of these companies perform their activities in the human health care field, followed by companies working in the agrifood biotechnology area.

Based on data published by Clarke, Modet & Co. and Udapi y Asociados, there were 374 biotech patent applications and 52 awards reported, submitted by 37 biotech companies. This survey, which is run parallel to that undertaken by the Madrid Science Park, takes into account all the patents within one same family and it is not constrained solely to the OPEM, EPO, USPTO and WIPO patent offices.

Graph 7:

Number of patent applications and awards for 2007 and 2008

Source: ASEBIO and MSP





Ap – Applications

Aw - Awards

Table 5: Industrial Property procedures of the ASEBIO spanish company members during 2008. Source: ASEBIO and MSP

Applicant	State	Number	Title / description
Advanced in vitro cell technologies	Ap	EP1937282	Chitosan and heparin nanoparticles
Araclon Biotech	Ap	EP19755179	Antibodies for detecting amyloid beta peptides Abeta40 and Abeta42
Archivel Farma	Ap	WO08053055	Tuberculosis vaccine based on cell wall fragments from a strain of Mycobacterium tuberculosis-complex.
Bioges Starter	Ap	ES2294871A1	Production of 3-hydroxyacyl-n-phenylakanoic acids through a strain of genetically manipulated Pseudomonas putida.
Biokit	Ap Ap	US20080190458 WO200897896	Magnetic particle washing station
Biokit	Ap Ap Ap	US20080193332 WO200897892 WO200897892	Apparatus and methods for dispensing sample holders
Biokit	Ap Ap	US20080192567 WO200897923	Reagent cartridge mixing tube
Biokit	Ap	USD560816	Cuvette
Biokit	Ap	USD565741	Mixing tube
Biokit	Ap	JP2008501980	Tapered cuvette and method of collecting magnetic particles
Biokit	Ap	JP2008502318	Compositions and methods for detecting pathogen infection
Bionostra	Ap Ap Ap	EP1904626 CN101278043 ES2310062	Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications
Bionostra	Ap Ap Ap	ES2294679 DE602005002621 ES2307346	Empty capsids (vlp(-VP4)) of the infectious bursal disease virus (ibdv), obtainment process and applications

Bionostra	Ap	ES2307345	Chimeric empty capsids of the infectious bursal disease virus (ibdv), obtainment process and applications
Biotherapix	Ap	WO2007113285	Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
	Ap	EP2007815	
Biotoools	D	GB200816954	Tablet holder
Biotoools	Ap	WO2008155560	Method for quantitative analysis of a material
Biotoools	Ap	WO2008149118	Sample preparation method for enhancement of nmr sensitivity
Biotoools	Ap	WO200887384	Charged particle analyser and method
	Ap	WO200887384	
Biotoools	Ap	EP1994422	Mnr spectroscopy with multiple-coil probes
Biotoools	Aw	EP1902327	Magnet assembly for dnp and/or nmr applications
Biotoools	Ap	EP1890766	Method of providing magnetised particles at a location
	Ap	JP2008546677	
Biotoools	Ap	EP1892302	Nucleic acid detection method involving the direct generation of a measurable signal
	Ap	JP2008543300	
Biotoools	Ap	JP2008534976	Method of operating a dynamic nuclear polarization system
Biotoools	Ap	US20080100293	Method of carrying out dynamic nuclear polarization
	Ap	JP2008528961	
Biotoools	Aw	AU2002246125	Method for preparing stabilised reaction mixtures, which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures
Calantia	Ap	WO200853059	Use of the ocp3 mutation to regulate drought resistance in plants
	Ap	ES2304304	
Canvax	Ap	WO200900281	Methods for directional cloning of amplified nucleic acids and uses thereof
Cellerix	D	GB200820397	Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
Cellerix	D	GB200817571	Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
Cellerix	D	GB200814249	Uses of mesenchymal stem cells
Cellerix	D	GB200809361	Injection device
Cellerix	Ap	EP1974019	Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
Cellerix	Ap	EP1926813	Cell populations having immunoregulatory activity, method for isolation and uses



Cellerix	Ap Ap	KR20080048555 CN101313062	Cell populations having immunoregulatory activity, method for isolation and uses
Cellerix	Ap Ap Ap Ap	EP1899458 KR20080036588 CN101263224 JP2008546397	Use of adipose tissue-derived stromal stem cells in treating fistula
Cellerix	Ap Ap	JP2008515413 ES2313805	Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue
Chimera	Ap	WO2008122310	Method for the detection of an analyte in biological matrix
Chimera	Ap Ap Ap	EP1904626 CN101278043 ES2310062	Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications
Dominion	Ap	EP1874723	New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof
Dominion	Ap	EP1951665	Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof
Era Biotech	D	GB200804213	A method of printing or preventing pain
Era Biotech	Ap Ap Ap	WO200796192 KR20080096848 EP1994145	Production of biologically active proteins
Era Biotech	Ap Ap Ap	CN101103114 JP2008521767 BR200517120	Protein isolation and purification
Era Biotech	Ap Ap Ap	CN101098886 JP2008521391 BR200517121	Production of proteins
Exxentia	Ap	WO2008152173	Phenolic extracts of almond peel containing procyanidins, propelargonidins and prodelphinidins, and method for preparation thereof
Fina Biotech	Ap	US20080318221	Method for the diagnosis and/or prognosis of alzheimer's disease
Fina Biotech	Ap	US20080318220	Method for the diagnosis and/or prognosis of alzheimer's disease
Fina Biotech	Ap	WO200865220	Protein-expression patterns in mononuclear cells as cardiovascular-disease markers

Fina Biotech	Ap	MX2007016136	Method for the diagnosis of alzheimer's disease
	Ap	KR20080034874	
	Ap	ES2301280	
	Ap	EP1961766	
	Ap	US20080206762	
	Ap	JP2008544242	
Fina Biotech	Ap	ES2307347	Method and kit for diagnosing the risk of developing a venous thrombotic disease.
Fina Biotech	Aw	RU2323440	Process for detecting predisposition to a cardiovascular disease
	Ap	NZ-534341	
Gaiker	Ap	WO2008116941	Method and device for detecting genetic material by means of polymerase chain reaction
Gaiker	Ap	EP1961405	Anti-bedsore mattress
Gaiker	Ap	ES2308888	Machine and method for disassembly of electronic components from printed circuit boards.
Gendiag	Ap	EP1947194	Method and device for the in vitro analysis of mrna of genes involved in haematological neoplasias
Genómica	D	GB200809881	Method for detecting respiratory viral agents in a test sample
Genómica	D	GB200803461	Device for detection of target-probe interactions
Genómica	Ap	WO200812576	Assay for diagnosing a predisposition to pathological bone conditions and anticipating response to treatment
	Ap	WO200812576	
Genómica	Ap	WO2007107789	Treatment of cns conditions
	Ap	AU2007228570	
	Ap	KR20080111063	
	Ap	EP2004823	
Genómica	Ap	EP1941037	Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases
Genómica	Ap	EP1937281	Modulation of trpv expression levels
Genómica	Ap	EP1910576	In vitro diagnostic kit for identification of human papillomavirus in clinical samples
	Ap	KR20080045167	
Genómica	Ap	CN101184480	Treatment of intestinal conditions by a compound which causes rna interference
	Ap	JP2008532540	
	Ap	US20080249048	
Genómica	Ap	JP2008511302	Methods and compositions to inhibit p2x7 receptor expression
	Ap	RU2007111321	
Genómica	Ap	JP2008510786	Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
	Ap	RU2007110646	



Grifols	Ap	ES2298096	Production method for concentrated von willebrand factor or complex of factor eight and von willebrand factor, involves preparing solution containing specific concentration and nanofiltering solution
Grifols	Aw	ES2294976	Method for obtaining human albumin, highly effective for use in detoxification therapy, involves carrying out dialysis phase and stabilizing solution with sodium chloride and amino acid
Grifols	Aw Ap Ap	ES2282054 US20080232986 EP1975408	Tubular pump
Grifols	Ap Ap Ap Aw Ap Ap Ap	CA2606352 US20080098830 CN101173955 ES2277573 EP1923137 JP2008116455 BR200703972	Device for loading reagent cards for clinical analysers
Grifols	Ap Ap Ap	CA2594921 EP1882486 US20080027382	Device for handling perfusion liquids with membrane filter and anti-tamper means
Grifols	Ap Ap Ap	CN101101293 JP2008003089 BR200702629	Suspension medium for red blood cells
Grifols	Ap Aw	HK1083601 ES2281222	Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia
Grifols	D E Aw Ap Ap	DE602005003426 PT1656954 US7332577 ES2294664 DE602005003426	Therapeutic human albumin solutions with low prekallikrein activator (PKA) activity and process for obtaining them
Grifols	Ap	US20080274974	Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
Grifols	Aw Aw Ap Aw D E	AU2004200745 EP1457497 ATE410438 US7442308 DE602004016900 PT1457497	Process for removing viruses in fibrinogen solutions

Grifols	Aw	EP1225180	Process for the production of virus-inactivated human gammaglobulin G
	Ap	ATE382631	
	D	DE60224310	
	Ap	HK1048324	
	E	PT1225180	
	Aw	JP4070468	
	Ap	ES2295308	
Ingenasa	Ap	WO08025843	Insects virus employment as adyuvantes for the promotion of answers humorales and adaptive set against antigens.
Intituto Biomar	Ap	WO2008152127	Terpenes with antifungal activity against malassezia yeasts
Intituto Biomar	Ap	EP1909912	Use of collismycin and derivatives thereof as oxidative stress inhibitors
Intituto Biomar	Ap	US20080275088	Use of collismycin and derivatives thereof as oxidative stress inhibitors
Intituto Biomar	D	DE602004010667	Cytotoxic depsipeptides
	E	PT1644403	
	Ap	NZ-544066	
	Ap	ES2297441	
	Ap	DK1644403T	
	Ap	US20080227765	
	Aw	US7446094	
	Ap	DE602004010667	
Juste SAQF	Ap	WO200810085	Prognostic method
	Ap	CA2657493	
	Ap	WO200810085	
Juste SAQF	Ap	WO200810084	Prognostic method
	Ap	CA2657616	
	Ap	WO200810084	
Laboratorios SANIFIT	Aw	ES2272191	Use of phytate for water treatment
	Ap	EP1966096	
Laboratorios SANIFIT	Ap	US20080110782	Myo-inositol hexaphosphate for topical use
Lab. Leti	Aw	EP1024829	Tolerogenic fragments of natural allergens
Natraceutical	Ap	WO200890237	Method for obtaining fibre-rich cocoa with low carbon hydrate and methylxanthine contents, suitable for animal feed, and resulting cocoa
Natraceutical	Ap	WO200800846	Method for sterilizing cocoa materials using super-critical CO ₂



Natraceutical	Ap Aw Ap	EP1886578 ES2277516 JP2008539706	Method of preparing a highly-soluble cocoa extract
Natraceutical	Ap Ap	US20080085357 JP2008525004	Microemulsion of polar antioxidants in edible oils
Natraceutical	Ap Ap	US20080014322 JP2008502339	Olive polyphenols concentrate
Natraceutical	Ap	EP1927288	Process for producing cocoa polyphenol concentrate
Natraceutical	Ap Aw Ap Ap D Aw Ap Ap	JP2008500380 EP1748700 RU2006119430 ATE385177 DE602005004613 GB2414393 ES2300999 US20080193629	Process for producing cocoa polyphenol concentrate
Neocodex	Ap Ap	WO200849953 WO200810195	In vitro method for prognosis and/or diagnosis of hypersensitivity to oestrogens or to substances with oestrogenic activity
Neocodex	Ap	EP1975255	Method and apparatus for the determination of genetic associations
Neocodex	Ap Ap	EP1947195 WO200776516	Method for the in vitro detection of a predisposition to the development of alterations in ovarian function
Neuroscience Technologies	Ap	EP1969513	Brain-based device having a cerebellar model for predictive motor control
Newbiotechnic	Aw	ES2273531	Employment of polinucleótidos as biotrazadores of food products to verify its authenticity..
Noscira	Ap Ap	EP2002863 WO2008152068	[1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
Noscira	Ap Ap Ap Ap	WO200815241 AU2007280400 CA2658552 EP1886990	Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders
Noscira	Ap Ap Ap	WO200815240 AU2007280399 CA2658547	N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
Noscira	Ap Ap	NO200804924 NO200804923	N- (2-thiazolyl) -amide derivatives as gsk-3 inhibitors
Noscira	Ap	RU2006139030	Thiadiazolidinones as GSK-3 inhibitors

Operon	Ap	JP2008517950	Amino or thiol linker building block for the synthesis of amino- or thiol-functionalized nucleic acids and methods of making and use thereof
Operon	Ap	US20080009613	Methods and compositions for determining the sequence of nucleic acid molecules
Operon	Ap	JP2008183012	Methods and compositions for determining the sequence of nucleic acid molecules
Oryzon Genomics	D	GB200724970	Treatment and prevention of neurodegenerative diseases
Oryzon Genomics	Ap	US20080318221	Method for the diagnosis and/or prognosis of Alzheimer's disease
Oryzon Genomics	Ap	US20080318220	Method for the diagnosis and/or prognosis of Alzheimer's disease
Oryzon Genomics	Ap	WO2008119767	Method of nucleic acid analysis.
Oryzon Genomics	Ap	WO2008119765	Method of nucleic acid analysis to analyze the methylation pattern of cpg islands in different samples
Oryzon Genomics	Ap Ap	ES2301342 EP2006393	Method for analysing nucleic acids
Oryzon Genomics	Ap Ap	ES2300176 EP2000543	Method for the molecular diagnosis of prostate cancer and kit for implementing same
Oryzon Genomics	Aw Ap Ap Ap	ES2277785 EP1980624 WO200774193 US20080286801	Method for the analysis of differential expression in colorectal cancer
Oryzon Genomics	Ap Ap	JP2008506406 ES2310057	Molecular diagnostic method and treatment in dementia with Lewy bodies
Oryzon Genomics	Ap	ES2292270	A method for selectively detecting subsets of nucleic acid molecules
Oryzon Genomics	Aw Ap D Ap	EP1034261 ATE396258 DE69839525 ES2306485	Method of parallel screening for insertion mutants and a kit to perform this method
Palau Pharma	Ap	CL1922008	Composed by-products of purina substituted; process of preparation; composition pharmaceutical; and use in the processing of illnesses such as refusal to transplant, leukemias, diabetes, among others.
Palau Pharma	Ap	EP2009009	Crystalline antifungal compounds
Palau Pharma	Ap Ap	WO2008119792 CL9462008	Pyrrolopyrimidine derivatives as jak3 inhibitors
Palau Pharma	Ap	WO200890181	Purine derivatives



Palau Pharma	Ap	WO200821049	Crystalline antifungal compounds
	Ap	AU2007284851	
	Ap	TW200823197	
	Ap	AR--62232	
	Ap	WO200821049	
	Ap	WO200821049	
Palau Pharma	Ap	EP1887004	Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one
Palau Pharma	Ap	EP1960400	Pyrazoloisoquinoline derivatives
Palau Pharma	Ap	TW200804375	Pyrazoloisoquinoline derivatives
	Ap	AR--58223	
	Ap	KR20080070687	
	Aw	NO20082105	
	Ap	US20080269209	
	Ap	CN101312974	
Palau Pharma	Ap	EP1940894	Triflusal-containing polymers for stent coating
Palau Pharma	Ap	KR20080059234	Triflusal-containing polymers for stent coating
	Ap	US20080249617	
	D	IL-190255	
Palau Pharma	Ap	EP1928862	2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
Palau Pharma	Ap	TW200800956	2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
	Aw	NO20081003	
	Ap	KR20080043840	
	Ap	CN101277951	
Palau Pharma	Ap	EP1907358	Bicyclic derivatives as p38 kinase inhibitors
Palau Pharma	Ap	MX2007015705	Bicyclic derivatives as p38 inhibitors
	Aw	NO20076345	
	Ap	KR20080029976	
	Ap	CN101213175	
	Ap	JP2008544965	
Palau Pharma	Ap	EP1917241	Bicyclic derivatives as p38 kinase inhibitors
Palau Pharma	Aw	NO20075987	Bicyclic derivatives as p38 kinase inhibitors
	Ap	AR--58010	
	Ap	ECSP088145	
	Ap	MX2007015531	
	Ap	KR20080028870	
	Ap	CN101208301	
	Ap	JP2008544964	

Palau Pharma	Ap	JP2008508341	Condensed pyridines as kinase inhibitors
	Ap	BR200514125	
	Ap	RU2007107910	
	Ap	US20080318977	
Palau Pharma	Aw	US7468376	Pyrazolopyridine derivatives
	Ap	NZ-541836	
Palau Pharma	Ap	US20080079460	New phosphoramidate derivatives
Palau Pharma	Aw	US7351836	Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives
	Aw	EP1424329	
	Ap	ATE396976	
	D	DE60226879	
	Ap	HK1066214	
	E	PT1424329	
	Ap	DK1424329T	
	Aw	NO-326162	
Palau Pharma	Ap	ES2307817	Sodium salt of an azo derivative of 5-aminosalicylic acid
	Ap	DK1272490T	
	Ap	ES2291320	
	Ap	DE60130444	
PharmaMar	Ap	KR20080053417	Antitumoral compounds
	D	GB200821701	
	D	GB200820808	
	D	GB200804758	
	D	GB200723376	
PharmaMar	Ap	WO2008135793	Combination of aplidine and carboplatin in anticancer treatments
PharmaMar	Ap	GB200708691	Pm00104 compound for use in cancer therapy
	Ap	WO2008135792	
PharmaMar	Ap	WO200880956	Prognostic molecular markers for the cancer therapy with aplidine
PharmaMar	Ap	WO200803809	Antitumour compounds
	Ap	ES2288795	
	Aw	ES2288795	
PharmaMar	Ap	TW200811128	Antitumoral dihydropyran-2-one compounds
	Ap	AR--61506	
PharmaMar	Ap	WO2007101235	Improved antitumoral treatments
	Ap	NO200804047	
	Ap	KR20080105123	



PharmaMar	Aw Ap Ap Ap	NO20083117 KR20080075911 EP1972633 CN101331137	Antitumour compounds
PharmaMar	Ap Ap Ap Ap	NO200802655 EP1951711 KR20080080095 CN101304991	Indole derivatives as antitumoural compounds
PharmaMar	Ap Ap Ap Ap D Ap	WO200752076 KR20080064959 NO200802425 EP1968592 IL-190774 CN101300011	Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
PharmaMar	Ap Ap Ap Ap	KR20080032641 MX2008001585 EP1925668 CN101278050	Genes involved in the biosynthesis of thiocoraline and heterologous production of same
PharmaMar	Ap Ap Ap Ap Ap Ap	NO200801083 AU2006274690 MX2008001548 EP1910326 KR20080034130 CN101233125 US20080234363	Antitumoral compounds
PharmaMar	Ap	EP1879870	Antitumoral tetrahydro-pyrimidines
PharmaMar	Ap Ap Ap	KR20080007640 CN101171236 JP2008540362	Antitumoral tetrahydro-pyrimidines
PharmaMar	Ap Ap Ap	ES2290844 DE602005001833 BR200517238	Formulations comprising ecteinascidin and a disaccharide
PharmaMar	Ap Ap Ap	CN101119750 JP2008517991 BRPI0518250	Pegylated liposomal doxorubicin in combination with ecteinascidin 743
PharmaMar	Ap Ap Ap	US20080076772 JP2008514688 US20080242670	Ecteinascidin compounds as anti-inflammatory agents
PharmaMar	Ap Ap	JP2008505862 US20080293725	Prognostic molecular markers
PharmaMar	Ap	JP2008506633	Convergent synthesis for kahalalide compounds

PharmaMar	Ap	US20080255132	Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
PharmaMar	Ap	CN101123966	Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
PharmaMar	Aw Ap D E	EP1689404 ATE406897 DE602004016376 PT1689404	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
PharmaMar	Ap Ap	EP1918296 SI1664093T	New antitumoral compounds
PharmaMar	Aw Ap D E Aw Ap Ap	EP1664093 ATE393776 DE602004013454 PT1664093 EP1664093 DK1664093T ES2305843	Antitumoral compounds based on Kahalalide F
PharmaMar	Ap Ap Aw Aw Ap D Aw E	US20080090121 NZ-541611 US7381703 EP1603584 ATE406171 DE602004016126 RU2335294 PT1603584	Aplidine for multiple myeloma treatment
PharmaMar	Aw Aw Ap Aw	UA--82089 CN100409895C NZ-541634 RU2341283	Improved antitumoral treatments
PharmaMar	Aw Ap Ap	US7323444 US20080090757 NZ-541493	Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
PharmaMar	Ap Ap Ap Aw Aw Ap	ES2289337 DE60314426 US20080103320 CN100390167C RU2328492 US20080269511	Total synthesis of myriaporones
PharmaMar	Aw Ap Aw Ap	AU2002334203 US20080119397 AU2002334203 US20080318848	Kahalalide compounds for use in cancer therapy



PharmaMar		EP1435991 ATE411036 DE60229414	Use of aplidine for the treatment of pancreatic cancer
PharmaMar	Ap	SI1414828T	Antitumoral analogs
PharmaMar	Ap	DK1414828T	Antitumoral analogs
	Aw	EP1414828	
	Ap	ES2294151	
	Ap	HK1065786	
	Aw	AU2002313540	
	Ap	DE60222775	
PharmaMar	Ap	SI1406907T	Antitumoral derivatives of Ecteinascidin ET-743
PharmaMar	Ap	DK1406907T	Antitumoral derivatives of et-743
	Ap	ES2291479	
	Ap	DE60222135	
	Aw	AU2002317967	
PharmaMar	Ap	AU2008207381	New antitumoral derivatives of ET-743
PharmaMar	Aw	EP1404668	Variolin derivatives and their use as antitumor agents
	Ap	ATE396987	
	D	DE60226869	
	Aw	AU2002317329	
	Ap	ES2307768	
PharmaMar	Ap	US20080033001	Derivatives of variolin b
	Aw	US7329666	
PharmaMar	Ap	SI1294747T	Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
PharmaMar	Ap	US20080009435	Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
	Aw	US7348310	
	Aw	EP1294747	
	Ap	ATE393775	
	D	DE60133817	
	E	PT1294747	
	Ap	HK1052940	
	Ap	DK1294747T	
	Ap	ES2305083	
PharmaMar	Ap	ES2293996	Antitumoral compounds
	Ap	DE60131076	
PharmaMar	Ap	SI1496060T	Antitumoral analogs of ET-743

PharmaMar	Ap	DK1254162T	Kahalalide f and related compounds
	Ap	HK1047290	
	Ap	ES2292558	
	Ap	DE60130192	
	Ap	US20080318849	
PharmaMar	Ap	ES2288486	Aplidine treatment of cancers
	Ap	DE60035120	
	Aw	BG--65381	
PharmaMar	Ap	SI1229922T	Aplidine treatment of cancers
PharmaMar	Ap	ES2290583	Hemisynthetic method and intermediates thereof
	Ap	US20080045713	
	Ap	US20080051407	
	Ap	DE60129753	
	Ap	US20080146580	
	Aw	US7410969	
	Aw	US7420051	
	Aw	RU2237063	
PharmaMar	Ap	CN101181272	Treatment of cancers
PharmaMar	Ap	DE60030554	Uses of et743 for treating cancer
	E	PT1702618	
	Ap	DK1702618T	
	Ap	ES2294756	
	I	NL-300337I	
	Ap	LU--91418	
	Aw	AU2005200180	
	I	NO2008005	
	Aw	PL-198185	
	I	DE122008000013	
	Ap	DE60036826	
	I	NL-300337I	
	Aw		
PharmaMar	Ap	SI1702618T	Use of et743 in combination therapy with dexamethasone for treating cancer
Solutex	Ap	EP1937281	Modulation of trpv expression levels
	Ap	EP1941037	
Solutex	Ap	EP2004823	Treatment of cns conditions
	Ap	WO2007107789	
Solutex	Ap	US20080249048	Methods and Compositions for the Treatment of Intestinal Conditions



Sylentis	Ap	WO2007107789	Treatment of cns conditions
	Ap	AU2007228570	
	Ap	KR20080111063	
	Ap	EP2004823	
Sylentis	Ap	EP1941037	Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases
Sylentis	Ap	EP1937281	Modulation of trpv expression levels
Sylentis	Ap	CN101184480	Treatment of intestinal conditions by a compound which causes rna interference
	Ap	JP2008532540	
	Ap	US20080249048	
Sylentis	Ap	JP2008511302	Methods and compositions to inhibit p2x7 receptor expression
	Ap	RU2007111321	
Sylentis	Ap	JP2008510786	Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
	Ap	RU2007110646	
Probelte	Ap	WO2008113873	A pure culture of strain ah2 of the bacillus velezensis species and a product for the biological control of phytopathogenic fungi
	Ap	ES2306600	
Probelte	Ap	EP1967079	Process and apparatus for preparing pomegranate extracts
	Ap	EP1967078	
	Ap	EP1967079	
Probelte	Ap	WO200890460	Process and apparatus for the production of hydroxytyrosol containing extract from olives and solids containing residues of olive oil extraction
Probelte	Ap	EP1953133	Process and apparatus for the production of hydroxytyrosol from olive oil extraction residues



Science Production

ASEBIO annually carries out an analysis of the publications made by Spanish biotech companies or multinational research laboratories based in Spain, in influential science publications.

This survey excludes press releases, posters in congresses or trade exhibitions and chapters in books. Neither do we include publications signed by research centres or universities which do not quote their relationship with studies for business projects.

There were a total of 140 publications recorded made by 22 Spanish companies. The most active companies in this field were the Progenika Group with 34 publications, the ZELTIA Group, PharmaMar and Noscira with 25 and 11, respectively, followed by Neocodex (23), BTI (9), Neuron Biopharma (6) and Cellerix (5).



**Table 6: Publications signed by ASEBIO spanish company members 2008.** Source: ASEBIO

Company	Publication	Article Title
Agrasys	2008, Euphytica 162:371–379.	Isolation of two storage protein promoters from Hordeum chilense and characterization of their expression patterns in transgenic wheat.
Agrasys	2009. Methods In Molecular Biology, Vol 478, Transgenic Wheat, Barley and Oats, Production and Characterization Protocols, Humana Press, ISBN978-1-58829-961-1 (Print) 978-1-59745-379-0	Transgenic Wheat, Barley and Oats, Production and Characterization. In: Methods In Molecular Biology,
Biobide	EBR: European BioPharmaceutical Review	Ainhoa Letamendia Urraca and Carles Carrol at Biobide look at automated screening to detect risk of cardiotoxicity in vivo
Biomedal	J Chromatogr A. (2008); 1208:189-196.	Affinity partitioning of proteins tagged with choline-binding modules in aqueous two-phase systems.
Biomedal	PLoS ONE (2008) 3:e2294.	Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide.
Biomedal	Am J Clin Nutr. (2008), 87:405-414.	Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide.
BTI	Trends Pharmacol Sci 2008;29:37-41	Delivering growth factors for therapeutics.
BTI	Frontiers Biosci 2008;13: 3532-3548.	Platelets and wound healing
BTI	Biomed Mater Res B 2008;84:415-421.	Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers
BTI	Clin Exp Rheumatol 2008;26:910-913	Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study
BTI	J Periodontology 2008;79:42-48	5 year clinical evaluation of short dental implants placed in posterior areas: a retrospective study
BTI	J Periodontology 2008;79: 1168-1176.	Clinical outcome of immediately loaded BTI dental implants: a 5-year retrospective study

BTI	J Clin Periodontology 2008;35:724-732.	5-year clinical experience with BTI dental implants: risk factors for implant failure
BTI	Pract Proced Aesthet Dent 2008;20(2):123-128	Novel protocols for a predictable implantology
BTI	Neuropsychiatr Dis Treat. 2008; 4:1073-1084	An integral approach to the etiopathogenesis of human neurodegenerative diseases (hndds) and cancer, possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS)
Cellerix	Tissue Engineering	Requirement of IFN- γ mediated Indoleamine 2,3 dioxygenase expression in the modulation of lymphocyte proliferation
Cellerix	Tissue Engineering: Part A. Volu 15. N° 00	Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications on immunogenicity
Cellerix	British Journal of 2008 Surgery, vol 95	Adipose-derived mesenchymal stem cells in biosutures do not improve healing of experimental colonic anasto
Cellerix	International Journal of Color- ectal disease	Treatment of enterocutaneous fistula in Crohn's disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion
Cellerix	Diseases of the Colon and Rectum Vol 52 79-86	Expanded Adipose-Derived: Stem Cells for the Treatment of Complex Perianal Fistula a Phase II Clinical Trial
Era7	Traffic	Characterization of a Listeria monocytogenes protein interfering with Rab5a.
GENETRIX	Carcinogenesis 29: 237-243. 2008	CDC6: from DNA replication to cell cycle checkpoints and oncogenesis.
Genomica	APMIS	Jose Javier Gomez Roman, et al.
Genomica	APMIS	Nina Mejlhede, et al
Genzyme	Biologics: Targets & Therapy.2008.2(4) 1-22	Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
Genzyme	Nature Clinical Practice Neph- rology.2008	Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
Genzyme	Kidney International .2008. 74(Suppl III)S29-S32)	Renal manifestations in Fabry disease and therapeutic options
Genzyme	Clinical Nephrology.2008. 69(6) 445-449	Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy.
Genzyme	Nephrol Dial Transplant.2008. 23 1600-1607	Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 256	Mass-Scale comprehensive RhD genotyping of 3000 samples using BLOODchip v 1.0.



Executive Summary

Grupo Progenika	Vox Sanguinis. 2009. 96(1): 256	Mass-Scale extensive genotyping of 3000 RBC samples by BLOODchip v 1.0.
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 252.	BLOODchip v2.0, a single test for human red blood cell and platelet antigens genotyping
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 27.	Mass-scale genotyping of RBC donors in the Basque Country.
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 251.	Detection of weak expression of D antigen among D negative C positive donors using RBC genotyping.
Grupo Progenika	Science. 14 March, 2008. (319).	Blood-Matching Goes Genetic.
Grupo Progenika	British Journal of Haematology. 2008. 144: 3–13.	Large-scale blood group genotyping – clinical implications.
Grupo Progenika	Clinica. 2008.: 13-16.	A year of superlatives for blood banking in the US.
Grupo Progenika	Rev Esp Cardiol. 2009; 62(1): 57-65	Análisis coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España.
Grupo Progenika	Journal of the American College of Cardiology. 2008; 52 (19)	Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting.
Grupo Progenika	The American Journal of Cardiology. Octubre 2008.	Comparison of genetic versus Clinical Diagnosis in Familial Hypercholesterolemia
Grupo Progenika	Atherosclerosis; 2008	Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
Grupo Progenika	Arterioscler. Thromb. Vasc. Biol. 2008; 28; 580-586	Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia: Influence Of The Genetic Defect
Grupo Progenika	International Journal of Clinical Practic; 2008	Diagnosis of heterozygous familial hypercholesterolaemia in children
Grupo Progenika	Toxicol Lett. 2009 Apr 10;186(1):45-51. Epub 2008 Oct 28.	The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
Grupo Progenika	Hum.Reprod. 2008.	Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis
Grupo Progenika	Transl.Res. 2008. 151:134-140.	Plexin B1 is downregulated in renal cell carcinomas and modulates cell growth.
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 256	Mass-Scale comprehensive RhD genotyping of 3000 samples using BLOODchip v 1.0.
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 256	Mass-Scale extensive genotyping of 3000 RBC samples by BLOODchip v 1.0.

Grupo Progenika	Vox Sanguinis. 2009. 96(1): 252.	BLOOchip v2.0, a single test for human red blood cell and platelet antigens genotyping
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 27.	Mass-scale genotyping of RBC donors in the Basque Country.
Grupo Progenika	Vox Sanguinis. 2009. 96(1): 251.	Detection of weak expression of D antigen among D negative C positive donors using RBC genotyping.
Grupo Progenika	Science. 14 March, 2008. (319).	Blood-Matching Goes Genetic.
Grupo Progenika	British Journal of Haematology. 2008. 144: 3–13.	Large-scale blood group genotyping – clinical implications.
Grupo Progenika	Clinica. 2008.: 13-16.	A year of superlatives for blood banking in the US.
Grupo Progenika	Rev Esp Cardiol. 2009; 62(1): 57-65	Análisis coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España.
Grupo Progenika	Journal of the American College of Cardiology. 2008; 52 (19)	Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting.
Grupo Progenika	The American Journal of Cardiology. Octubre 2008.	Comparison of genetic versus Clinical Diagnosis in Familial Hypercholesterolemia
Grupo Progenika	Atherosclerosis; 2008	Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
Grupo Progenika	Arterioscler. Thromb. Vasc. Biol. 2008; 28; 580-586	Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia:Influence Of The Genetic Defect
Grupo Progenika	International Journal of Clinical Practic; 2008	Diagnosis of heterozygous familial hypercholesterolemia in children
Grupo Progenika	Toxicol Lett. 2009 Apr 10;186(1):45-51. Epub 2008 Oct 28.	The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
Grupo Progenika	Hum.Reprod. 2008.	Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis
Grupo Progenika	Transl.Res. 2008. 151:134-140.	Plexin B1 is downregulated in renal cell carcinomas and modulates cell growth.
Histocell	Farmaespaña Industrial	Salas blancas en terapia avanzada
Intelligent Pharma	Current Computer-Aided Drug Design. (in press) 2009.	Explicit Treatment of Water Molecules in Protein-Ligand Docking.
Lipopharma	J. Cell. Mol. Med.	Minerval induces apoptosis in Jurkat and other cancer cells
Lipopharma	J. Cell. Mol. Med	Membranes: a meeting point for lipids, proteins and therapies



Lipopharma	Biochimica et Biophysica Acta	Membrane interactions of G proteins and other related proteins
Neocodex	Journal of Health Nutrition and Aging (in press).	GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE e4 carriers
Neocodex	Neurogenetics. 2009 Jan 21. [Epub ahead of print]	Whole-genome conditional two-locus analysis identifies novel candidate genes for late-onset Parkinson's disease
Neocodex	. Journal of Acquired Immune Deficiency Syndrome 2008 Oct 1;49(2):128-35.	Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load and clinical progression
Neocodex	Journal of Endocrine Investigation 31:618-623, 2008.	Allelic Imbalance analysis of EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma
Neocodex	Cardiovascular Diabetology 2008 Jul 25;7:23.	The peroxisome proliferator-activated receptor delta gene is associated with obesity and interacts with the calpain 5 gene to modulate the phenotype
Neocodex	BMC Genomics. 2008 Jul 31;9:360.	A method for detecting epistasis in genome-wide studies using case-control multi-locus association analysis
Neocodex	PLoS ONE. 2008 Aug 13;3(8):e2953.	The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population.
Neocodex	Cuadernos de Medicina Reproductiva CMR-2008. Vol. 14. Nº 2 (capítulo libro)	Introducción a la medicina genómica y predictiva
Neocodex	Metab Brain Dis. 2008 Dec 10.	Gut ammonia production and its modulation
Neocodex	Immunogenetics. 2008 Aug;60(8):439-47. Epub 2008 Jun 11.	Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
Neocodex	Genet Epidemiol. 2008 Jul;32(5):445-53.	Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds
Neocodex	Cancer Immunol Immunother. 2008 May 20. [Epub ahead of print]	Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations
Neocodex	BMC Cancer. 2008 Apr 21;8:110.	Methylation alterations are not a major cause of PTTG1 misregulation
Neocodex	Reproductive Sciences 2008 Apr;15(3):305-11	A Digenic Combination of Polymorphisms Within ESR1 and ESR2 Genes Are Associated With Age at Menarche in the Spanish Population
Neocodex	Journal of Medical Genetics. 2008 Jul;45(7):420-4. Epub 2008 Apr 18.	Identification of a 2244 base-pair interstitial deletion within the human ESR1 gene in the Spanish Population

Neocodex	Medical Science Monitor. 2008 Mar;14(3):CR136-43.	Analysis of the ERalpha germline PvuII marker in breast cancer risk
Neocodex	Oncology Report 2007 Dec;18(6):1583-7.	Analysis of CXCL12 3'UTR G. A polymorphism in colorectal cancer
Neocodex	Fertil Steril. 2007 Sep 28; PMID: 17905236	Association of genetic markers within the BMP15 gene with anovulation and infertility in women with polycystic ovary syndrome
Neocodex	J Gastroenterol Hepatol. 2007 Jun 7; PMID: 17559371	Identification of a protective haplogenotype within CAPN10 gene influencing colorectal cancer susceptibility
Neocodex	Clin Chem. 2007 Jun; 53: 1162-64. No abstract available	Pyrosequencing Technology for Automated Detection of the BMP15 A180T Variant in Spanish Postmenopausal Women
Neocodex	Eur J Surg Oncol. 2007 Mar 21; PMID: 17382509	CAPN10 alleles modify laryngeal cancer risk in the Spanish population
Neocodex	Clin Chem. 2007 Jan;53(1):91-7. PMID: 17110473	Endothelial nitric oxide synthase haplotypes are associated with features of metabolic syndrome
Neocodex	European Journal of human Genetics 2007 PMID: 17609672	Genetic analysis of the GRM1 gene in human melanoma susceptibility
Neuron Biopharma	Zebrafish	Zebrafish as a new model for herpes simplex virus type 1 infection
Neuron Biopharma	Revista Alimentaria	El pez cebra, un modelo incipiente para la evaluación de ingredientes
Neuron Biopharma	Revista Alimentaria	Producción de lípidos por fermentación
Neuron Biopharma	Progress in Drug Research	Strain improvement for production of pharmaceuticals and other microbial metabolites by fermentation
Neuron Biopharma	Biocatalysis&Biotransformation	Alteration of substrate specificity of Galactomyces geotrichum BT107 lipase I on eicosapentaenoic acid-rich triglycerides. Biocatalysis & Biotransformation.
Neuron Biopharma	Anaerobe	Metabolism of prebiotic products containing beta(2-1) fructan mixtures by two Lactobacillus strains.
Neuroscience Technologies	J Physiol	Re-emerging microneurography
Neuroscience Technologies	Neurology	Neuropathic pain: redefinition and a grading system for clinical and research purposes
NorayBio	Applied Information and Communication Technologies. Proceedings of the International Scientific Conference. Jelgava, Latvia	"NorayLiver:Bioinformatics platform to help in Genomic, Proteomic or Metabolomic marker discovery for liver diseases"



Noscira	The Journal of Biological Chemistry	A delta-catenin signaling pathway leading to dendritic protrusions.
Noscira	Journal of Alzheimer's disease	Risk factors for dementia of Alzheimer type and ageing-associated cognitive decline in a Spanish population based sample, and in brains with pathology confirmed Alzheimer's disease
Noscira	Progress in Neuropsychopharmacology & Biological Psychiatry	Antidepressant-like effect of novel thiazolidinone NP031115
Noscira	Neuro-degenerative Diseases	Potent beta-amyloid modulators
Noscira	En: Jiménez Jiménez FJ, Luquin MR, Molina JA, Linazasoro G (Eds.): "Tratado de los trastornos del Movimiento".	Demencia con cuerpos de Lewy
Noscira	Alzheimer Disease and Associated Disorders	A Randomized, Double-Blind, Placebo Controlled-Trial of Triflusal in Mild Cognitive Impairment: the TRIMCI study
Noscira	"Neurodegenerative Diseases: From Molecular Concepts to Therapeutic Targets." von Bernhardt R, and Inestrosa NC (Eds.)	Glycogen Synthase Kinase 3 (GSK-3) As A Molecular Target for Alzheimer's Disease and Other Tauopathies
Noscira	Current Opinion in Drug Discovery & Development	Glycogen Synthase Kinase-3 (GSK-3) Inhibitors Reach the Clinic
Noscira	Current Opinion in Drug Discovery & Development	Glycogen Synthase Kinase-3 (GSK-3) Inhibitors Reach the Clinic
Noscira	FEBS Letters	NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice
Noscira	Journal of Geriatric Physical Therapy	Normative data and determinants for the timed up and go test in a population-based sample of elderly individuals without gait disturbances
Palau Pharma	Eur J Drug Metab Pharmacokinet	Antihistaminic effects of rupatadine and PKPD modelling.
PharmaMar	Br J Cancer	Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma
PharmaMar	Cancer Res	Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
PharmaMar	Mol Biosyst	Characterization of TioF, a tryptophan 2,3-dioxygenase involved in 3-hydroxyquinolinate formation during thiocoraline biosynthesis
PharmaMar	Expert Opin Pharmacother	Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

PharmaMar	J Nat Prod	Cytotoxic Staurosporines from the Marine Ascidian <i>Cystodytes solitus</i>
PharmaMar	Eur J Cancer	In vitro radiosensitisation by trabectedin in human cancer cell lines
PharmaMar	Clin Pharmacol Ther	Mechanism-based Pharmacokinetic/ Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia
PharmaMar	Bioconjug Chem	N,N,N',N'-Tetramethylchloroformamidinium Hexafluorophosphate (TCFH), a Powerful Coupling Reagent for Bioconjugation
PharmaMar	Oncogene	Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway
PharmaMar	Clin Cancer Res	Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors
PharmaMar	Clin Cancer Res	Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors
PharmaMar	Lung Cancer	Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
PharmaMar	Lung Cancer	Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer
PharmaMar	J Pharmacol Exp Ther	Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/JNK activation in human melanoma cells
PharmaMar	Mol Cancer Ther	Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
PharmaMar	Cancer Chemother Pharmacol	Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
PharmaMar	Eur J Pharmacol	Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKC α activation
PharmaMar	J Med Chem	Structure-Activity Relationship of Kahalalide F Synthetic Analogues
PharmaMar	J Med Chem	Synthesis and Antitumor Activity of Mechercharmycin A Analogues
PharmaMar	Clin Cancer Res	Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma



PharmaMar	Magn Reson Chem	Structure elucidation and $^1\text{H}/^{13}\text{C}$ NMR spectral assignments of four trabectedin related compounds
PharmaMar	Cancer Chemother Pharmacol	Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects
PharmaMar	Curr Opin Investig Drugs	Neuroinflammatory diseases and the importance of a healthy blood-brain barrier
PharmaMar	Cancer Res	Levels of SCS7/FA2H-Mediated Fatty Acid 2-Hydroxylation Determine the Sensitivity of Cells to Antitumor PM02734
PharmaMar	Eur J Cancer	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
Sistemas Genómicos	Progr Diag Trat Prenat (2008) 18: 74-78	Recomendaciones de calidad para el diagnóstico prenatal molecular.
Sistemas Genómicos	J Assist Reprod Genet (2009). In press	Quality management system in PGD/PGS: now is the time.
Sylentis	Infect. Disord Drug Targets 8(4):262-73 December 2008.	RNA interference-based therapeutics: new strategies to fight infectious disease



5. RED OR HEALTHCARE BIOTECHNOLOGY

The most outstanding advances in 2008 within the Therapy Development field were those by Noscira, which began Phase II studies of the NP-12, Araclon Biotech, obtaining its first European patent for a vaccine as therapy for Alzheimer's Disease and PharmaMar which was authorised to market Yondelis in Spain.

The diagnostics products and services area was headed by Fina Biotech, which is working on a method for diagnostics and/or prognosis of Alzheimer's disease, Histocell and Neuron Bph, which have developed a diagnostics kit for verifying drug effectiveness on the same disease and Araclon Biotech which has developed a kit for its prediction. Alternatively, Omnia Molecular have created a new technology which allows an antibiotic to be developed in less than 2 years.

In the bioinformatics area, Intelligent Pharma has 4 computer programmes for designing new drugs and Bioalma created 2 "Aks2" tools for finding relationships between genes, diseases and drugs and "Novoseek" for undertaking intelligent online searches of biomedical literature.

In animal health care the most outstanding enterprises were Palau Pharma, which began Phase II studies of Cimicoxib for treating the inflammation process in animals, Ingenasa, which developed a diagnostics kit for early detection of the blue-tongue pathogen virus and a kit for detecting and characterising brucellosis.





6. GREEN BIOTECHNOLOGY

During 2008, there was a significant rise in the world acreage used for biotech crop production, reaching a figure of 2,000 million acres (800 million hectares), which represents a rise of 9.4% (10.7 million acres) from 2007 to 2008 (www.isaa.org).

In 2008 Spain reached 14th position with an area which came to 79,269 hectares according to data published by the Ministry of the Environment and Rural and Marine Areas (http://www.mapa.es/agricultura/pags/semillas/estadisticas/serie_maizgm98_06.pdf), concentrated on crops sown in the Ebro valley and other areas suffering frequent corn borer attacks. With this figure, Spain heads the EU countries which cultivate genetically modified (GM) varieties and it is also the leading importer of grain for feeding a powerful cattle raising sector, on which many thousands of jobs depend.

In the agrifood area, worthy of mention were the creation of new functional ingredients such as those developed by Agrasys, Natraceutical, Neuron Bph and Puleva Biotech-Exxentia.

7. WHITE OR INDUSTRIAL BIOTECHNOLOGY

In the last quarter of 2008 there was a highly significant legislative drive in the biofuel area, both on a national and at European level. In October 2008, the Spanish Ministry of Industry, Tourism and Trade passed the Renewable Energies Plan 2005-2010 whereby in 2009 3.4% of fuel used should come from biofuel sources and this figure would rise to 5.83% for 2010.

There are currently companies that are developing biodiesel from a variety of raw materials such as raw glycerine or live micro-organisms.

As far as bioremediation and biodetergents are concerned, companies that launched products onto the market in 2008 included Inteman, the producer of "Bio100 BtecnoClean" to eliminate oils, grease and other filth from floors, using micro-organisms that act on the joints in the flooring, A&B Laboratorios which also received the European Ecolabel for an enzyme-based

multiple cleaner for the industrial and agrifood sectors this year and Clean Biotech which has developed Phytodesal for soil desalination using phyto salt accumulators and Halodepur, a process of biopurification of hypersaline waste waters.

8. THE FINANCIAL ENVIRONMENT

The 2008 tax year saw a fall in the number and volume of investment operations in the biotech sector with respect to other years.

The Public Sphere: The National Innovation Enterprise (Spanish initials ENISA) and the Centre for Technological and Industrial Development (Spanish initials CDTI) were the public bodies entering into most financial operations in the Spanish biotech sector.

Table 7: Main financial operations in the Spanish biotech sector in 2008.

Source: Drawn up from data from ASEBIO members, information published in the press and by the Spanish Venture Capital Association (Spanish initials, ASCRI)

Company	Investor	Concept	Investment (€ million)
Natraceutical	Ibersuizas	Acquisition (5%)	13.48
Cellerix	ETV Capital	Loan	10.00
Infinita Renovables	Xesgalicia	Equity loan	10.00
Oryzon Genomics	Corsabe / Laboratorios Ordesa	Capital increase	9.00
Era Biotech	Axis, Highgrowth, Uninvest , BCN Empren, 2 private investors	Early phases	4.60
Bionergética Extremeña	Catalana d'Iniciatives	-	2.80



Coretherapix	European Commission	Approval FP7 project	2.00
Vivia Biotech	Suan Biotech FCR, Ronda Vida (Clave Mayor) and ADE Capital Sodical	Capital increase	1.85
Nanobiomatters	Axón	-	1.80
Archivel Farma	Archivel Technologies, FON-SINNOCAT	Capital increase	1.70
Palau Pharma	Najeti Capital	-	1.70
Dominion Pharmakine	Dominion Biozone, S.L	Capital increase	1.50
Canvax	Dominion Biozone, S.L	Capital increase	1.20
Neurotec Pharma	CDTI/CAN/Acció/private investors	-	1.10
Aleria Biodevices	CDTI / Seed Capital / Caixa Capital Semilla	Expansion	1.00
Biomedal	Suan Biotech FCR y Invercaria	Capital increase	1.00
AB-Biotics	Business Angels	Capital increase	1.00
Ysios Bio Fund FCR	Sodena/Talde	-	0.90
Suan Biotech FCR	Xesgalicia	Start-up	0.82
Activery	Sodena	Expansion	0.75
Histocell	Noraybio Group	Capital increase	0.70
Valentia Biopharma	CDTI	NEOTEC	0.60
Farm Biocontrol	ENISA/Sodiari	-	0.45
Genmédica Therapeutics	ENISA	Start-up	0.45
Sanifit	Caixa Capital Risc y Business Angels	Capital increase	0.44
General Equipment For Medical Imaging	ENISA	Expansion	0.40
Neocodex Reprofilling	Invercaria	Equity loan	0.40
Agrasys	UNINVEST	Capital increase	0.36
Archivel Farma	ENISA	Start-up	0.30
Biótica	Clave Mayor	Start-up	0.29
Biogas Fuel Cell	ENISA	Expansion	0.25

Biorganic Research And Services	ENISA	Expansion	0.25
Abyntek Biopharma	ENISA	Expansion	0.20
Bioapter	CDTI/ENISA	Start-up	0.20
Genosa I+D	ENISA	Expansion	0.20
Ikerchem	CDTI	Start-up	0.20
Integromics	ENISA	Expansion	0.20
Biotech Vana	ENISA	Start-up	0.15
Neuroscience Technologies	Socios	Capital increase	0.13
Xenotechs Laboratorios	ENISA	Start-up	0.13
Valentia Biopharma	Inversiones Valencia	Capital increase	0.13
Bioftalmik	CDTI	Expansion	0.10
Agrocontrol 2007	Iniciativas Económicas de Almería	Seed capital	0.06
Abba Gaia	CDTI	NEOTEC	Not available
Advancell	Talde	Expansion	Not available
Applied Research Using Omic Sciences	CDTI	-	Not available
Axeb Biotech	CDTI	-	Not available
Azurebio	CDTI	-	Not available
Bioalma	Möbius	Start-up	Not available
Bioglane	CDTI	-	Not available
Bioingenium	CDTI	-	Not available
Biomaslinic	CDTI	-	Not available
Biomat USA Inc	Cofides	-	Not available
Catfosc Health Made To Measure	CDTI	-	Not available
Cellerix	Ysios	Acquisition (7,62%)	Not available
Cooclea	CDTI	-	Not available
Halotech Dna	CDTI	-	Not available
Iline Microsystems	CDTI	-	Not available



Ingelia	CDTI	-	Not available
Innoprot	Seed Capital de Bizkaia	Start-up	Not available
Innovative Technologies In Biological Systems	CDTI	-	Not available
Morpheus Medical	CDTI	-	Not available
PCB	Innova 31	Partial Acquisition	Not available
Proretina Therapeutics	CDTI	-	Not available
Sabirmedical	CDTI	-	Not available
Técnicas Y Procesos Agrícolas	CDTI	-	Not available
Veracetics	CDTI	-	Not available

Private sphere

Some private venture capital funds have extended their areas of activity to include biotechnology as one of their target sectors.

In September 2008, Ysios Capital Partners formalised Ysios Biofund I, a fund specialising in biotechnology with an endowment of €67 million, in order to finance 10 biotech enterprises.


After a round of funding, Era Biotech, a company manufacturing recombinant proteins obtained €2.8 million from the financial entities Axis, Highgrowth and Uninvest, receiving €1.5 million, €1 million and €300,000, respectively.

As regards acquisitions, the most outstanding operation was the merger between Oryzon Genomics and Crystax.

9. INTERNATIONALISATION

According to a survey taken by ASEBIO, approximately 30% of its membership exported during 2008, reaching a figure of €108 billion (up 52% over 2007) to 42 countries worldwide.

Spanish biotech companies export both products and services related to R&D, most particularly in the Biomedicine field and to a certain extent in the agrifood sector. As far as the product exports were concerned, the most representative were diagnostics kits and reagents and products in support of research work, while the most prominent service exports included technical consultancy in biotechnology and contracts for R&D work.






Executive Summary

The main receiver markets for Spanish exports were the European Union, where 92% of the survey respondents market their products; the United States and the southern cone of the Americas, reporting 52%; and Japan, China and the Middle East, where 30% of the companies are trading.

Graph 9: % of exporting companies by export destination. Source: ASEBIO




Growth in sales activity was a generalised feature, as 86% of the exporting enterprises recorded increases in their foreign sales in 2008.

International Partnerships

In addition to embracing foreign markets from a sales viewpoint, Spanish biotech companies also collaborate with foreign partners for other purposes: R&D, undertaking surveys and studies, licences, etc. The number of this kind of alliances has grown continuously since 2005, although in 2008, there were 23 collaboration agreements identified between ASEBIO members and partners from 12 countries, figures slightly down on those of the previous year.

Graph 10: Evolution of the number of international partnerships entered into by Spanish biotech companies/institutions 2005-2008. Source: ASEBIO




	2005	2006	2007	2008
No. of partnerships	2	21	25	23



Graph 11: Geographical spread of international partnerships entered into by Spanish biotech companies/institutions in the period 2005-2008 (figures of partnerships per year).

Source: ASEBIO




The biotech companies have gradually diversified the geographic origin of their collaborating partners, going from collaborations largely with North American or European enterprises, to forging partnerships which are much more geographically widespread. Hence in 2008 and for the first time, collaborations with North American or EU companies or institutions did not reach 50% of the total, while there was a rise in partnerships with other European and Latin American countries.

Spain in the International Context

In the last OECD report on data from 2006 both company creation and R&D investment are both worthy of mention.

Of all the OECD members¹, Spain recorded the highest growth rate between 2004 and 2006 in numbers of companies with biotech activity (+53%) and also in fully biotech companies (+30%). In 2006, Spain was in eighth place as regards the number of fully biotech companies, just behind Holland, and ahead of countries like Switzerland, Finland or Austria.




¹ The member countries of the OECD are: Australia, Austria, Canada, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Korea, Luxemburg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States.



Executive Summary

In R&D investment, Spain was also the OECD country reporting the highest growth from 2004 to 2006, lying in ninth place overall as regards total investment (expenditure) in biotech R&D. Despite this significant growth and total investment (expenditure) in R&D placing Spain up with countries at the forefront of the sector in Europe, spending per capital still stands far below the European average.

Graph 13: Expenditure/Investment in R&D in millions € PPP\$² per country. Source: OECD



² PPP\$ Purchasing Power Parity: A model for determining the exchange rate whereby the price of a good in one country must be equal to the price of the same good in another country, after making adjustments for price variations due to exchange rate variations.



biospain
2010

5th International Meeting
on Biotechnology

September 29 - October 1 2010

Pamplona - Spain

About

biospain
2010

BIOSPAIN is the top biotechnology event in Spain, organized by **ASEBIO** - the Spanish Bioindustry Association and **SODENA** - Navarre's government development agency. Since the first edition, launched back in the year 2003, it has become one of the leading biotechnology events in Europe.

BIOSPAIN 2010 will feature a trade exhibition, partnering event, investment forum, scientific congress, seminars and career fair with a well-balanced mixture of local and international private companies, universities, overseas clusters, research institutes and governmental bodies.

CONTACT

Navarra Consultores de Comunicación S.L.
C/ Navas de Tolosa, 19 - 2ª Dcha
31002 Pamplona. Navarra. Spain

Phone: +34 948 22 39 82

Fax: +34 948 22 34 20


E-mail: maria@ncsl.com
dfernandez@asebio.com

www.biospain2010.org

Profile of participants (based on Biospain 2008)


By Industry

Biotech 41%
Clusters & Technology parks 12%
CRO - CRO - Services 12%
Pharma 10%
Investors 9%
Bioinformatics 7%
Others 9%




By Position

Top management 38%
Senior management 37%
Middle management 25%



By Region

Europe 79%
North America 12%
South America 10%
Asia Pacific 3%
Middle East 3%



> Apply to reserve your exhibition space now!

25 SODENA
SOCIETAT DE UNIFORMS DE NAVARRA

asebio



FIVE EXAMPLES OF THE PRESENCE OF SPANISH BIOTECH COMPANIES AT AN INTERNATIONAL LEVEL

We should highlight the Spanish biotech sector's endeavour last year to attain a greater international presence. Below are some examples of some entities beyond our borders and their interest in each country.

The interest held by Spanish biotech enterprises goes far beyond collaboration agreements with North American entities, which continue to record notable growth in the biotech sphere. This is the case of PharmaMar, which now has a sales office in New York, or Progenika, which with a significant international expansion now has a development and production centre in Massachussets and also a laboratory in the Arab Emirates and sales and intellectual property management offices in Madrid and London.

Alternatively, in 2008 NorayBio opened a delegation in Italy to attend the Italian, Swiss and French markets. Its exports account for 5% of its sales, although they are expected to reach between 10% and 15% by 2011. The company will base its international expansion on a clear commitment to launching new products onto the market and in R&D, with investments in the latter coming to €1.3 million in the last four years.

Although modern biotechnology was born and driven by the developed countries, other less forward countries has been able to discover the importance biotechnology may come to have in their production processes, on their economy. Chile, whose companies are focused on the development of biological pest control, medical and veterinary diagnostics and enzymes, or Argentina, one of the world's most important producers of transgenic crops

and industrial enzymes, the biopharmaceutical industry, diagnosis or veterinary vaccines are just some examples. Alternatively, Brazil has been able to harness the potential biotechnology has to offer it. Through a now developed biotech sector, its future prospects are promising: Its science production, its collaboration networks and its companies, concentrated in Sao Paulo and Minas Gerais are particularly outstanding in the seed market and in genetic improvement of plants, bioinformatics and human health care.

A clear example of Spanish presence in Brazil is the Spanish company Biotoools. This company markets its products and services both in Spain and in Europe, Asia, the Americas and Arab countries. For its international distribution it uses local distributors and it has an associate sales company in Brazil, with a range of plans for international expansion. Biotoools obtains 40% of its sales in the international market. It markets its products through distributors in 30 different countries.

Lastly, one of the cases which best illustrates Spanish internationalisation in this sector is Natraceutical. The company currently has production plants in Spain, the United Kingdom, Switzerland, Australia and Brazil, is actively present in over 60 countries from all five continents and has its own sales offices in Europe, the United States and the Asia-Pacific region.





aseptic



Appendix 1, Who is who?

ASEBIO Members



Business Members

- Red biotechnology
- Green biotechnology
- White biotechnology
- Services



3P Biopharmaceuticals



Mission > Development of production systems and production of active therapeutic principles for studies pre clinical, clinical phases I, II and III, and in some commercial case. Processes using yeasts, bacterial fermentation and cells of mammals. Processes under cGMP conditions Processes of cellular therapy and cellular culture.

Products > Development of expression systems and production of proteins. Proteins, Interleukins, monoclonal antibodies, vaccines and adyuvantes. Other therapeutic substances of peptidic nature. Development of production systems and elaboration units of cellular therapy. Development services and cultivation of cells. Elaboration DMF (Drug Master File). Service of Regulatory

Interest areas > Projects to industrialize products and services in cellular therapy or cellular culture. Biosimilars development. Collaboration with companies non EU in adaptation to the European market and regulatory. Integral service of development, production, dose systems, and clinical until arriving to the registration like medication, well for the own capacities or with the associate companies

Contact > tel.: +34 948 346 480 Dámaso Molero
http://www.3pbio.com dmolero@3pbio.com



A&B Laboratorios en Biotecnología, S.A



Mission > Development of bioproducts for biodegredients and bioremediation products

Products > Research, manufacturing and marketing of industrial chemical and biological products.

Interest areas > Selection of natural micro-organisms. Enzyme production. Industrial fermentation. Ecodesign

Contact > tel.: +34 945 291 616 Jon Kepa Izaguirre
http://www.ab-laboratorios.com kepa@ab-laboratorios.com



AB Biotics

Mission >	Development of medicaments (AB-THERAPEUTICS) and creation of a Laboratory of Genetics (AB-GENOTYPING).	
Products >	Service of R+D for companies and elaboration of products for license.	
Interest areas >	Project development with collaboration with other companies (CENIT).	
Contact >	tel.: +34 902 903 844	Miquel A. Bonachera miquel@ab-biotics.com

Adecco Medical & Science

Adecco Medical & Science

Mission >	Provide HR services for the medical, science, pharmaceutical and biotechnology industries such as search and selection services of specialized profiles, specialized training and HR consulting with a proven know-how within each area.	
Products >	Search and selection services for medical & science profiles focused in research, sales and marketing activities within the pharmaceutical & biotechnology sectors. Technical training consulting for the pharmaceutical and science areas. Occupational health & safety consulting.	
Interest areas >	Participation in working groups, publications and workshops. Provide business solutions to different needs in the HR area.	
Contact >	tel.: +34 932722870 http://www.adecco.com	Oscar Porcel Oscar.porcel@adecco.com



Business Members



Advancell in Vitro Cell Technologies, S.L.

Mission >	To contribute to obtaining new medicines through new technologies acquired in Spanish universities and / or developed by Advancell. Developing and marketing "in vitro" cell models in service or product form (kits). Developing Advancell technologies and products until the clinical concept trial stage.	
Products >	CacoReady: a tool designed to optimise pre-clinical screening regarding the viability of orally administering compounds of a different nature. HUVECs: Umbilical vein endothelial cells. HUAECs: Umbilical artery endothelial cells. Microsomes. Adipocytes. KITS (under development): AdipoCell /MicrosomeCell. Others.	
Services >	Screening. Customised research: ADME, cancer, inflammation, biocompatibility, cosmetics and skin biology. Pharmaceutical developments. ADV-P1 (chronic lymphocytic leukaemia B cells). ADV-P2 (diabetes). ADV-P3 (psoriasis). ADV-P4 (haemodynamics). ADV-P5 (solid tumour progression)	
Interest areas >	Technologies or products in early phases, complementary or with strategic value for ADVAN-CELL: Cancer, Cosmetics, Others	
Contact >	tel.: +34 93.403.45.45 http://www.advancell.net	Kenneth Weissmahr ken.weissmahr@gmail.com



Agrasys, S.L.

Mission >	AGRASYS is a R&D-based company which uses advanced plant breeding technologies to produce novel crop varieties with added value. These new varieties are targeted at specific market opportunities, identified by the company or its business partners. Current projects and products of the company are directed at the market sectors of functional foods and biofuel crops.	
Products >	The first product being brought to market is a novel cereal type which offers health benefits and can be used in the production of a range of cereal-based foods. The same techniques are used in the development of improved food crop varieties for bioethanol. The company has experience of consultancy in the Agbiotech area.	
Interest areas >	Agrasys works with companies and public research centers, as the technology provider, contractor of research services or partner in product development and marketing. Examples of collaborations; breeding of new crop germplasm as raw material for food or industrial uses, co-development of new food applications based on varieties with functional components, genetic engineering of industrial crops.	
Contact >	tel.: +34 93 4020278 http://www.agrasys.es	Pilar Barceló Ensena pilarbarcelo@agrasys.es



Alexion Pharma Spain SL

Mission >	Pharmaceutical product development and commercialization.	
Products >	Humanized monoclonal antibody for the treatment of the Paroxistic Nocturnal Hemoglobinuria.	
Interest areas >	Biotechnology applied to general medicine. Innovative drugs. Orfan drugs commercialization in rare diseases.	
Contact >	tel.: +34 93 344 32 60 http://www.alxn.com/	Jordi Casals casalsj@alxn.com



Alma Consulting Group Spain

Mission >	Our mission is to identify and obtain financing and savings for our customers. We contribute to our client's competitiveness through measurable actions. Professionals of ALMA Consulting Group work day by day to boost your growth through Innovation, providing the resources you need to finance your Research and Development potential, with a constant commitment for optimisation and security.	
Products >	Areas of expertise: Financing of Innovation. Property Tax. Non-strategic purchasing: energy, telecoms, office cleaning, temporary manpower.	
Interest areas >	We create a long-term partnership with our customers in order to provide an outstanding support to improve their results.	
Contact >	tel.: +34 91 575 03 01 http://www.almacg.com	Marta Orueta/Juan Antonio Costa morueta@almacg.com, jacosta@almacg.com

Alphasip

Contact >	tel.: +34 626 00 41 07 http://www.alphasip.es/	Miguel Roncales mroncales@alphasip
---------------------	---	---------------------------------------



Amgen, S.A

Mission > To be the best company in human therapies, using science and patient service innovation.

Products > Treatments for the complementary care cancer and anaemia, rheumatoid arthritis and other autoimmune diseases. Amgen carries out active research programmes in nephrology, haematology, oncology, inflammations, metabolic, and bone disorders and neuroscience.

Contact > tel.: +34 936 001 900
http://www.amgen.es

Juan Carlos Esteban
jesteban@amgen.com



Araclon Biotech, S.L.

Mission > Research and development of neurodegenerative diseases therapies and diagnostics methods.

Products > Under development: Alzheimer disease blood diagnostic tests. Alzheimer disease therapy.

Contact > tel.: +34 976 796 562
http://www.araclon.com/

Guillermo de Vilchez Lafuente
gdevilchez@araclon.com



Archivel Farma, S.L.

Mission > Clinical development of vaccines

Products > Therapeutic vaccine against Latent Tuberculosis Infection

Interest areas > Research and Development on new biological drugs

Contact > tel.: +34 934 972 456
http://www.archivelfarma.com

Jaume Amat
archivel@archivelfarma.com



Arquebio



Mission > ARQUEBIO S.L. was created in 2007 by a highly experienced team in industrial life-sciences and chemistry with great R&D+i network. The company offers alternatives to industrial chemical synthesis processes through developing bioprocesses based on microbial fermentation. Own research and contract research and a collaborative approach allows offering state-of-the-art knowledge and profitable technology transfer to industrial customers.

Products > Chem to Biotech (C2B) implies the substitution or modification of traditional chemical synthesis reactions by biotechnological approaches, which comprise either the use of wild type and recombinant bacteria, yeasts and molds, or their products, such as enzymes. Nanotechnology for Biomedicine (N4B) takes profit of the same technological platform to obtaining products by fermentation (recombinant proteins and polymers) and develop delivery systems for drugs (Drug Carriers) and nucleic acids (Gene Therapy). These Delivery Systems can improve efficacy and decrease secondary effects in Oncology, Neurodegenerative diseases and other therapeutic fields.

Interest areas > Chemical, cosmetic, pharmacy, biotechnological and veterinary companies interested into introducing biotransformations in their manufacturing processes or interested in the evaluation and development of new approaches based on products obtained by microbial fermentation. ARQUEBIO collaborates with private and public research groups.

Contact > el.: +34 934 581 516
http://www.arquebio.com

Jaume Mir Ph.D.
jaume.mir@arquebio.com



Artbiochem, S.L.



Mission > Investigation and development of new enzymes and biomolecules. Development of new test for determination and quantification of metabolites using artichoke peroxidase

Products > Peroxidase, Protease, High DP Inulin, Polyphenol Extract from Artichoke. R+D Services from extraction and purification of enzymes and others biomolecules.

Interest areas > Development of new applications from high Dp inulin in biomedical sector. Development of tests for clinical diagnostics with companies of this sector for the detection of different diseases. Associates' search for the distribution of our products. Bioremediation. Microbiology y Fermentation.

Contact > tel.: +34 968 688 229
http://www.artbiochem.com

Jose Luis Vidal / Francisco Palazón
jlvidal@artbiochem.com; fpalazon@artbiochem.com



Asteria Biotech, S.L.

Mission > Biological potenciador for the growth and vegetal development, to biological agriculture and integral, obtained from extracts of marine microalgae and microalgae green-blue

Products > Nutritional supplements for human consumption. Additives for animal foods. Biofertilizers for agriculture

Contact >	tel.: +34 902.110.190 http://www.asteriabiotech.eu	Alberto Perez Pardo info@asteriabiotech.eu
---------------------	--	---



Bayer CropScience

Bayer BioScience N.V.

Mission > Bayer Bioscience N.V. is one of the main biotech innovation centres of Bayer CropScience AG, a subgroup of Bayer AG. The objective of the excellence centre is to integrate plant biotech research with the business demands of BayerBioscience to optimise innovating processes in a responsible and sustainable way. Drawing up crop management solutions (pest and weed control), researchers use genetic engineering to discover new features.

Products > Patents, know how. Crops of high agronomic interest, with new features applied to modern crossing techniques.

Interest areas > Agriculture, Environment-Biotechnology

Contact >	tel.: +34 955 65 58 70 http://www.bayercropscience.com	Maica Martinez maica.martinez@bayercropscience.com
---------------------	---	--



Bioalma

Mission >	Bioalma's objective is the development of information systems that help the researcher in biomedicine to manage and analyze the information in the literature, to research more efficiently and to reduce the development time of new products	
Services >	Novoseek is a biological knowledge system that manages information extracted directly from the scientific literature using the most advanced text mining techniques. It provides powerful search and visualization capabilities to navigate the knowledge network and contains functionality to easily identify relevant information.	
Interest areas >	Bioalma is interested in the application of information technology techniques on other biomedical bibliographic sources different from the scientific literature and the collaboration with biotech companies for the development of product that use information extraction for target discovery and validation and functional analysis of groups of genes or proteins.	
Contact >	tel.: +34 91 141 7150 http://www.bioalma.com	Luis Cornide lcornide@bioalma.com



Bioaurum Solutions, S.L.

Mission >	Technology Transfer and Innovation Management in Life Sciences Spreading biotechnology uses in traditional sectors and in rural areas	
Services >	NStrategic Consulting in Life Science Sector. Designing public policies in Biotechnology sector. Managing Private-Public consortium	
Contact >	tel.: +34 913 197 603 http://www.bio-aurum.com	Fidel Rodríguez Batalla froba@bio-aurum.com



Biobide

Mission > Biobide is a newly founded biotech company for the testing or automatic screening of new potential drugs using the zebra fish as the model animal. Biobide is structured on a technological platform that integrates zebra fish disease models, robotics, optical analysis and bio-IT tools, producing highly informative, low-cost results that give rise to a competitive advantage for companies involved in pharmaceutical product development.

Services > Functional genomics services. Action mechanism studies. Protein function studies. Biological route dissection. Toxicity Assay. Oncology: metastasis. Antiangiogenic. Diseases models generation in zebra fish. Identification and validation of therapeutic targets. Personalized tests.

Interest areas > The collaboration agreements subscribed by the company include both public and private research centres and companies. Company policy consists of setting up agreements with agents who not only possess quality research capacity but also undertake applied research projects that are complementary to our company's own activities, thus maximising the investment on all fronts.

Contact > tel.: +34 943 309 360
http://www.biobide.es

Idoia Ruiz de Azua
ruizdeazua@biobide.es



Bioftalmik

Mission > Our main objective is to design and develop diagnostic, prognostic and therapeutic systems for eye diseases and Biodevices for ophthalmic surgery.

Services > Integral R&D platform. Diagnostic tests. Clinical trials

Interest areas > Our strategy clearly promotes scientific, technical and clinical collaboration and all its manifestations as the most effective ways to innovate. Our main areas of interest are: Ophthalmology, therapy, diagnostic, prognostic, cell culture, molecular biology, proteins, drug development and drug delivery.

Contact > tel.: +34 944.069.659
http://www.bioftalmik.com

Jon Careaga
Jon.careaga@bioftalmik.com



Bio-Ges Starters

Products > Starters for the agricultural and food industry

Contact > tel.: +34 987 87 61 35
http://www.bioges.es/

Agustín Florez Moran
marian@serfisa.es



Biokit, S.A.

Mission > Research, production and distribution of clinical diagnostic reagents (IVD)

Products > Over 120 diagnostic products for the field of infectious diseases and plasmatic proteins. Reagents: 5 differentiated products depending on the different technologies used: Manual tests. Immunoturbimetric tests. Immunochromatographic tests. Immunoenzyme assay. Chemoluminescence. Raw materials: High quality antigens for hepatitis B, rubella, toxoplasma, Lyme disease, syphilis, VHS1 and streptolysin-O, together with antibodies for hepatitis B, streptolysin-O, rotavirus, PCR and ferritin.

Contact > tel.: +34 93 860 90 00
http://www.biokit.com

Joan Guixer
jguixer@biokit.com



BioMarin Europe Ltd. Sucursal en España

Mission > BioMarin seeks to develop product candidates that: Address currently unmet medical needs. Suggest a clear-cut development profile. Provide an opportunity to be first-to-market.

Products > Naglazyme. Aldurazyme. Kuvan

Interest areas > Metabolic Diseases. Enzyme Replacement Therapies

Contact > tel.: +34 800 808 508
http://www.bmrn.com/

Felis Iglesias
figlesias@bmrn.com



BioMaslinic, S.L.

Mission >	Manufacture and supplier, acknowledgement and applications of Maslinic Acid and Hidroxitirosol.	
Products >	Animal growth promoter, nutraceuticals, functional foods and antiinflammatory indications.	
Interest areas >	Maslinic acid has demonstrated a high selective apoptotic capacity over tumoral cells, based in the description of its route of activity. The experiments "in vivo" have been developed having a great success. Now BioMaslinic S.L. is working about its potential pharmaceutical application. So collaboration is needed to carry on different studies along the different phases of investigation, and also alliances to advance its development and marketing.	
Contact >	tel.: +34 958 750 981	José Prados Osuna biomaslinic@biomaslinic.es



Biomedal, S.L.

Mission >	To develop new, innovating technologies for the progress of post- genomic research and the efficient industrial production of new biomolecules that are useful for society.	
Products >	Genetic engineering tools for cloning, expression and purification of recombinant proteins and their related products	
Services >	The design of specialised strains, production of recombinant proteins, sequencing, DNA synthesis, DNA analysis, consultancy and technology transfer	
Interest areas >	Expression and purification of recombinant proteins, protein analysis, molecular diagnostics, proteomics, etc.	
Contact >	tel.: +34 954 081 276 http://www.biomedal.com	Ángel Cebolla Ramírez acebolla@biomedal.com



Biomol-Informatics



Mission >	BIOMOL-INFORMATICS is a company of bioinformatics services able to generate added value in research, diagnostics and pharmaceutical industry. We offer advising in the use and interpretation of state-of-the-art bioinformatic software applied to molecular biology and biomedicine.	
Services >	BIOMOL-INFORMATICS offers consulting services on Bioinformatics in areas of research, diagnostics and pharmaceutical industry. BIOMOL-INFORMATICS is specialist in "in silico" analysis and prediction of new drugs activity on 3D models of proteins and in molecular dynamics techniques applied to docking of compounds.	
Interest areas >	R&D projects: Bioinformatic modeling of Carnitine Palmitoyltransferase I enzyme: "in silico" design of anti-obesity drugs. Molecular dynamics simulation of polymerization and depolymerization processes of bacterial septum protein FtsZ: "in silico" design of specific inhibitors to be used as antibacterial drugs. "Divinocell" project financed by 7FP - EU.	
Contact >	tel.: 647504634 http://www.bioinfo.es	Dr. Paulino Gómez-Puertas bioinfo@bioinfo.es



Bionet Engineering



Mission >	To provide engineering services and turnkey construction of process package units for the biotech industry (fermentation, downstream, purification, isolation...). Our commitment to our clients means that we offer an integrated service for the whole project life cycle; from lab to industrial facilities and process start up.	
Products >	Lab to Market Engineering [L2M]. From process development at lab-scale we offer: Feasibility studies. Industrialization and scale-up studies. Turnkey construction of pilot plants. Pilot plant testing. Project management of biotech investments: Basic and detailed engineering. Project management or turnkey construction of industrial facilities. Commissioning and start up according to GMPs	
Interest areas >	Technology centres and R&D departments with new processes that want to add value to the Process Technology Package through a viability study, from an engineering point of view, considering existing / potential investors. New industrial investment projects and facilities that want to introduce a new process / product or that simply want to revamp an existing one. Technology centres that can collaborate in process optimization and troubleshooting.	
Contact >	tel.: +34 902 170 704 http://www.bionet.com	Enrique López enrique.lopez@bionet.com



Bionostra Group

Mission >	To develop new molecular biology applications (genomics, proteomics, HTS, combining biology, recombinants, etc.) in order to identify molecules with industrial/ pharmaceutical applications and to complete the range of diagnostic and detection kits available.	
Products >	Production of antibodies and recombinant proteins. Formulation kit. Vaccines. Microarrays. Bionostra: R + D of vaccines of new generation and biotech services in animal health, human health and agrifood area. Bioalma: bioinformatics solutions. Microbionta: investigation of therapeutic antibodies for the human health	
Interest areas >	Detection and quantification of GMOs in foods. Identification and authentication of species. Genotyping. Marker selection	
Contact >	tel.: +34 91 8060068 http://www.bionostra.com	Ana Carmen Martin anac@bionostra.com



Bioorganic Research And Services S.L. (Bionaturis)

Mission >	To develop and manufacture biotechnology products in a sustainable way for the diagnosis, prevention, and treatment of human and animal diseases.	
Products >	Customized difficult to express Recombinant Proteins at industrial level	
Services >	FLYLIFE® manufactures recombinant proteins at industrial scale, using insect larvae as bio-factories. We offer customized manufacture contract (CMO) for pharmaceutical, biotechnology, veterinary, and diagnostic companies. BIONATURIS acts as CMO offering the following advantages: High-versatile protein expression. High expression and proper folding. Cost-effective. Easy to scale-up. Reduced up-front Capital Investment, time-to-market, and operational costs. Biological safety. Devoid compounds of animal origin. Designed under cGMP international guidelines. Get access to manufacturing to SMEs.	
Interest areas >	Bionaturis has early-stage product programs underway, targeting diseases with unmet medical needs within specialty markets. The team is committed to build up a biopharmaceutical pipeline.	
Contact >	tel.: +34 956547346 http://www.bionaturis.com	Victor Infante victor.infante@bionaturis.com



Biopolis, S.L.



Mission >	Research projects and microbial biotech development.	
Products >	The design, selection, characterisation and production by fermentation of bacteria, yeasts and filamentous fungi and cellular metabolites obtained from these (proteins, enzymes, nucleic acids, polysaccharides). Fine tuning of its industrial applications in the agrifoodstuff and pharmaceutical fields.	
Contact >	tel.: +34 963 160 299 http://www.biopolis.es	Marta Tortajada Marta.tortajada@biopolis.es



Bioserentia



Mission >	Partner with companies, entrepreneurs, investors, governments to create and accelerate Ventures in Life Sciences.	
Services >	<ul style="list-style-type: none"> • Corporate Strategy, Strategic Investments in Life Sciences • R&D Strategy and Management • Fund Raising • BioEntrepreneurship Platform • BioBusiness Incubation & Acceleration • Interim Management • Commercial, Sales & Operational Support 	
Contact >	tel.: 914 311 970 http://www.bioserentia.com	Jorge Arenas-Vidal jarenas@bioserentia.com



Biot



Mission > BIOT is a Biotech Enterprise group focus on innovation and R&D in Microbiology. Goals are achieved from the interaction between different BIOT Companies and Research Groups from Universities, Research Institutes and other Companies as well. BIOT develops reliable solutions, products and methodologies based on microorganisms in the areas of agro-food, environmental and bioenergy production

Products > Selected strains of high biotechnological interest for different industrial sectors: Probiotics. Biofuel producers: methane, ethanol and biodiesel. Bioplastic producers. Soil and water decontamination. Enzymes and biomolecules from microorganisms of high industrial interest. Genetic constructions for improving microbiological processes

Services > Selection, isolation, quantification and identification of microorganisms using biochemistry and genetics techniques. Genetic Engineering Service of microorganisms. Analysis of microbial communities in terrestrial and aquatic ecosystems. Design and conservation of microbiological resources and culture collections of biotechnological interest. Consulting and advice in the field of Microbiology. Innovation, R&D Project Performing and Management.

Interest areas > Renewable energies production. Remainders. Biofuel production. Residual, industrial and urban water purification. Biorremediation. Functional food and nutrition-health. New active biomolecules. Nourishing industry. Security and microbiological control. Projects of I+D+i in cooperation

Contact > tel.: +34 958750618
http://www.biot.es

Agustín Lasserrot
direccion@biot.es



Biotechnet I+D, S.A.



Contact > tel.: +34 91 468 08 00

José Anduiza
pquintan@faes.es



Biotherapix Molecular Medicines S.L.U.

Mission >	Biotherapix Molecular Medicines S.L.U. is a company belonging to the Genetrix Group, which specialises in human antibodies and molecules derived from them. Its activity centres of the generation of new therapeutic molecules based on antibodies for the treatment of infectious, degenerative and inflammatory diseases. Its technology platforms make it a company competitive in the development of therapeutic molecules of a biological origin.	
Interest areas >	Molecular therapy. Protein biology. Protein production and purification systems. Development of therapeutic antibodies. Inflammation. Infectious diseases	
Contact >	tel.: +34 91 806 30 89 http://www.biotherapix.com	Juan Sebastián Ruiz jsruiz@genetrix.es



Biotools B&M Labs, S.A.

Mission >	Research, development, manufacture and commercialization of enzymes, kits, microarrays and biochips for biomedical research, agrofood control, medical diagnosis and prognosis as well as pharmacogenomics.	
Products >	Thermostable enzymes and other reagents for nucleic acid amplification. Nucleic acid extraction kits. Molecular Diagnostic Kits by Real Time (tuberculosis, HPV, ect..) using its own patented technology LIONPROBESTM. Stabilization services and technology transfer of reaction complex mixtures, through its own patented technology GELIFICATION. Cholest-chipTM, genomic expression microarrays, tissue microarrays. Design, manufacture, process and validation services of DNA and tissue microarrays. Distribution of laboratory equipment.	
Interest areas >	Biomedical research, microarray development and biomarkers.	
Contact >	tel.: +34 917100074 http://www.biotools.net	Antoine Bach, PhD, MBA bach@biotools.eu ; srodriguez@biotools.eu



Bosques Naturales, S.A.

Mission >	Promotion and maintenance of fine wood forestry plantations. This activity has a triple function: Sustainability, Productivity and Innovation. Bosques Naturales is a company leading research and development which applies vegetal biotechnology and intensive agronomic techniques to its production processes. Its lines of research in forestry biotechnology are oriented to genetic characterization of vegetal material in order to improve the volume and quality of wood.	
Products >	Plantations of high economic value trees using selected vegetal material which is reproduced "in vitro". The company has a Vegetal Tissue Growth Unit which provides its own germplasm bank.	
Services >	Bosques Naturales covers all the growth and maintenance costs of the trees during the twenty or twenty-five years which their productive cycle lasts.	
Contact >	tel.: +34 91 360 42 00 http://www.bosquesnaturales.com	Teresa Jiménez teresajimenez@bosquesnaturales.com



BTI Biotechnology Institute

Mission >	Continued research and development of new bone regeneration products and techniques.	
Products >	Plasma rich in growth factors (PRGF). Surgical Devices. Research and development. Dental implants. Surgical and prosthetic instruments. Publisher of "Dental Dialogue". BTI Scan (Diagnostic software for oral implants and oral surgery). Continuing in-service training centre	
Interest areas >	Tissue engineering and bone regeneration	
Contact >	tel.: +34 945 140 024 http://www.bti-implant.es http://www.prgf.net	Dr. Eduardo Anitua Aldecoa eduardo.anitua@bti-implant.es



Calantia Biotech, S.L.

Mission > Calantia Biotech was created in 2005. Its mission is to contribute to the efficiency of the energy sector's processes by means of biotechnological approaches. Although the development of specific scientific competencies is necessary for this purpose, the company also has the ability to imagine, feel and create new solutions.

Services > Calantia Biotech does avant-garde research aimed at eliminating the technological barriers of the bioenergy sector, and at improving the productivity of each step of the biofuels generation process through: identification and selection of non-traditional crops with high energy potential, implementation and genetic improvement of bioenergy crops (resistance to drought, fungus and virus, among others), enhancement of the processes to obtain biofuels (degradation of cellulose, among others) and exploitation of industrial residues proceeding from these processes (biotransformation into products with increasing demand in other sectors): development of the overall concept of biorefinery.

Contact > tel.: +34 96 199 42 33 Mamen Lladró
http://www.calantia.com mlladro@calantia.com



Canvax Biotech S.L.

Mission > The search for antigens for vaccines

Products > Own technology for the identification of antigens inducing T CD4+ and CD8+ response.

Interest areas > Vaccine sector, model animals for protection against infections

Contact > tel.: +34 957 420870 Elier Paz Rojas
http://www.dominion.es/index.html e.paz@dominion.es



Ceifer, S.L.

Mission > Human fertility study and research

Products > Assisted reproduction techniques, freezing of human fertility cells.

Contact > tel.: +34 958254 112 Juan Pablo Ramírez López
http://www.ceifer.com info@ceifer.com



Cellerix, S.A.

Mission > Cellerix, SA is a biopharmaceutical company, that was spun off from Genetrix in 2004. Cellerix is specialized in the clinical development of cell therapies. The products developed by the Company are living medicines that act upon the body in a natural manner thanks to the therapeutic potential of adult stem cells.
At present, the company has two products in clinical stage development (one of which is now in a phase III clinical trial), as well as several preclinical stage programmes.

Products > Ontaril® is Cellerix® proposal for the treatment of complex perianal fistulas (phase III clinical evaluation). Cx501 is Cellerix® proposal for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) (Phase II/III). Allogeneic Development is comprised in the Cx601 and Cx611 programmes, which take advantage of the intrinsic properties of eASCs. Cx611 is based on the systemic delivery of eASCs and will be developed to target larger autoimmune diseases

Interest areas > Cell therapy. Regenerative medicine. Tissue engineering. Cell medicines. Regulatory issues concerning cell therapy

Contact >	tel.: +34 918049264 http://www.cellerix.com	Jorge Alemany jalemany@cellerix.com
---------------------	--	---



Chimera Pharma

Mission > Development of immunotherapeutic vaccines against major indications in human health (infectious disease, cancer y cardiovascular)

Products > Universal influenza vaccine – Preclinical. Therapeutic cervical cancer vaccine – Preclinical. Lung cancer vaccine - R&D. Cardiovascular vaccine - R&D

Interest areas > Looking to establish collaboration with companies and research institutions with extracellular (cell bound or soluble) therapeutic targets relevant to human disease and susceptible to immunotherapeutic approaches.

Contact >	tel.: +34 91 141 7150 http://www.chimera-pharma.com	Arcado García de Castro agarcia@bionostra.com
---------------------	--	---



Clean Biotec



Mission > Find solutions to resolve environmental pollution problems using clean, sustainable and economical technologies. Improve the natural regulation capacity of ecosystems to reduce environmental impacts. New ways of natural and controlled systems for waste elimination and recycling

Products > Ecodiagnostics. Environmental audit reports. Waste assesment projects. Paleobotanic studies. Implantation and control of biomonitoring networks. Phytoremediation and Bioremediation. R & D biorremediation projects. Restoration of degraded lands. Research and improvement of new phyto and bioremediators. Microorganism research from extreme environments to use in bioremediation and other biotechnological applications

Interest areas > Environmental microbiology. Bioremediation. Biomonitoring. Metagenomics

Contact >	tel.: +34 941 238 261 http://www.clean-biotec.com	Nathalie Beaucourt nathalie@clean-biotec.com
---------------------	--	--



CPQ Ingenieros S.L.



Mission > CPQPharma division's prime objective is to provide highly professional consultancy, process and detail engineering and supervision services for the industrial projects of pharmaceutical and biopharmaceutical companies.

Services > Basic and detail engineering and supervision for pharmaceutical and biopharmaceutical companies. Pilot Plant design. Process and bioprocess scale-up. Cost Estimation of biopharmaceutical facilities.

Interest areas > Pharmaceutical and Biopharmaceutical Industrial installations. Cost Estimation of Biopharmaceutical Industrial Installations. Pilot Plant Design. Process and Bioprocess Scale-Up. Industrial Biotechnology. Industrial Nanotechnology

Contact >	tel.: +34 932478830 http://www.cpqingenieros.com	Ricard Gené rgene@cpqingenieros.com
---------------------	--	---



Digna Biotech, S.L.

Mission > To give value to the research undertaken in the CIMA (University of Navarre Applied Medical Research Centre) by means of preclinical and clinical development of the intellectual property generated by the researchers there.

Products > ANTIFIBROTICS: P144 (Schlerodermia, Actinic keratosis, Skin Cancer, ect&) License to ISDIN. P17 (Bone Metastasis, Macular Degeneration). ANTIVIRAL: INFa5 (hepatitis C). STIMULANTS FOR HEPATIC REGENERATION: Cardiotrofina (Hepatic resection, Hepatic transplant, Kidney transplant). IMMUNOMODULATORS: MTA (Multiple Sclerosis), EDA (vaccine adjuvant). GENE THERAPY: Vector Porphyria (Porphyria) License to AMT, Vector IGF-1 (cirrosis) License to AMT

Contact >	tel.: +34 911852510 http://www.dignabiotech.com	Maite Soria msoria@dignabiotech.com
---------------------	--	---



Diomune

Mission > Diomune S.L is a biotechnology company with the following aims: Research, development and marketing of new treatments, products and immunology services oriented to human and animal health areas in infectious, inflammatory and autoimmune diseases.

Products > Our main business areas are: developing a drug to cure Canine Leishmaniosis, Research and Development on drugs for the treatment of human septicaemia, and the establishment of license agreements with other companies to use our products as vaccine adjuvants.

Interest areas > Our major interest in collaboration is Vaccine Development. Diomune has a potential immunomodulator able to direct immune responses to be used as vaccine adjuvant. We are looking forward to find partners interested in using them as adjuvant in their vaccines or as immunomodulator in Immune-based diseases.

Contact >	tel.: +34 91 345 9214 http://www.diomune.com	Carolina Egea cegea@diomune.com
---------------------	--	---



EntreChem, S.L.

Mission >	Our objective is the discovery and development of bioactive new chemical entities (NCEs) from microbial natural products. We generate novel analogs by combinatorial biosynthesis of the corresponding metabolic pathways, identify the most promising candidates and advanced the preclinical development until demonstration of efficacy "in vivo".	
Products >	EntreChem offers genetic engineering for identification and manipulation of metabolic pathways from bacterial natural products of interest in the pharmaceutical (antibiotics, antitumorals, antifungals) and agro (insecticides, herbicides) sectors. EntreChem offers enantiopure products for medicinal chemistry and services of applied biocatalysis, as well as custom synthesis of optically pure compounds.	
Interest areas >	Discovery and development of new drugs from natural products by genetic engineering and biocatalysis. Antitumor and antitumor activity assays (cellular and biochemical), target identification. Early preclinical "in vivo" studies (efficacy, PK). Bioprocess scale-up.	
Contact >	tel.: +34 985 259021 http://www.entrechem.com	Francisco Morís info@entrechem.com



ERA Biotech

Contact >	tel.: +34 934 034 773 http://www.erabiotech.com/	François Arcand info@erabiotech.com
---------------------	--	---



Business Members



Era7 Information Technologies, S.L. (Era7)

Mission >	To help biotech companies and organizations in the biomedical field to take advantage of Information Technologies for a better information and knowledge management. With this objective in mind we design and provide advanced software solutions specially based on Internet technologies.	
Products >	Palinsight Pro: software for DNA palindromicity analysis and representation. Livera7: Software specially designed to manage and held real time virtual Congresses and workshops.	
Services >	Services of Knowledge Expression. Services of custom software development of Web applications, intranets, Web platforms and bioinformatics workflows automation. Bioinformatics and biosciences consultancy services.	
Interest areas >	Bioinformatics software development. Participation in R&D and innovation projects including participation in the EU VII Framework Program. Agreements for marketing and distribution of our services and products.	
Contact >	tel.: +34 958 750 629 http://www.era7.com	Eduardo Pareja epareja@era7.com



Esmedagro, S.L.

Mission >	Advising companies in the agrifood and environmental sectors that wish to improve their competitiveness through active participation in European R & D, individual and cooperative, national or international. We offer a comprehensive service in project management from our 5 branches in Spain and Portugal	
Services >	Consulting and Training in R & D. Feasibility studies for projects. Search for funding and partners for projects. Processing and justification of the regional, national and international aids. Development of Preliminary, Technical and Justification Reports. Coordination, Management and Monitoring of R & D projects. Field Trials	
Interest areas >	Companies interested in contacting a consultancy to the presentation of projects in national or international cooperation. Companies seeking involvement of some Spanish agri-food company in one of its projects, since we have a wide portfolio of clients to put in touch with. Platforms or agro-technology networks.	
Contact >	tel.: +34 902104595 http://www.esmedagro.com	Luis Alberto Alonso Beltrán de Heredia laabh@esmedagro.com



Esteve

Mission >	Esteve is an R&D oriented company with a commitment to provide society with new therapeutic solutions with a high innovating value.	
Products >	Esteve's activity lies in the pharmaceutical field, where it undertakes the research and development of new drugs in the area of prescription products, pharmaceutical advertising specialties, Vaccines, Hospital and Veterinary products, together with the production of drug active components.	
Contact >	tel.: +34 93 446 60 00 http://www.esteve.com	Dr. Eduard Valentí evalenti@esteve.es



EuroGalenus Executive Search

Mission >	Contribute to the identification and development of the best executives in the Biotechnology field.	
Services >	Since 1992, recruitment of Board positions, non-executive Directors and senior Scientists. Experience in Biotechnology, Diagnostics, Devices, Electromedicine, Pharmaceuticals, Nutrition, Cosmetics, Veterinary, and their Service companies.	
Interest areas >	Recruitment, training, HR consultancy.	
Contact >	tel.: +34 91-350 5556/7414 http://www.eurogalenus.com	Luis Truchado informacion@eurogalenus.com



Eurosemillas, S.A.

Mission >	To be a company of reference in the farming world, committed to agricultural development in the geographical areas where it is present.	
Products >	Select seeds. CottonGrain: cotton grain animal feed. Cotton fibre. Oleaginous oils. Development of licences for various plants: Fruit trees. Strawberry. Citrus fruits. Raspberry. Others: avocado pears, asparagus, etc.	
Services >	Farming news portal http://terraagraria.es . Development of an electronic commerce platform	
Interest areas >	Select seeds. Genetic improvement. Biotechnology. Development of plant varieties. Farming portal. Extraction of vegetable oils and cotton fibre	
Contact >	tel.: +34 957 421 732 http://www.eurosemillas.com	José Pellicer eurosemillas@eurosemillas.com



Farm Biocontrol, S.L.

Mission >	Our mission is provided with the highest biosafety level to pig, cattle, poultry and fish farms.	
Products >	Expert Consultancy and elaboration of reports and Action Plans. Systems to the slurry treatment. Systems to the gas emission reduction. Pest Control. Waters and Effluents Control. Salmonella Control. Laboratory Analysis. Training for technicians, managers and staff. Hazard Identification and Analysis of Critical Control Points.	
Interest areas >	Biotechnology. Biosafety and hygiene. Food traceability. Agriculture. Farms disinfection. Water treatment. Food Industry. Fish farms	
Contact >	tel.: +34 976 660 114 http://www.farmbiocontrol.com/	Nuria Porras / Rafael Arlegui internacional@farmbiocontrol.com ; r.arlegui@farmbiocontrol.com



FinaBiotech, S.L.

- Mission >** The search for kits for diagnosis, prognosis and/ or response to cancer treatment, to cardiovascular and neurodegenerative diseases and others. Therapy with adult stem cells. Licence or sale of products resulting from research to interested companies.
- Products >** HALOSPERM®, a kit for the diagnosis of male fertility based on DNA fragmentation. F12®, kit for genetic risk of thrombosis.
- Contact >** tel.: +34 917 991 564 José-Cándido Arochena Amestoy
<http://www.finabiotech.es/> Jc_arochena@finabiotech.es



Gendiag

- Mission >** GENDIAG is a research-driven biotech which aims to facilitate the personalized medicine by offering to the society new genetic diagnostic tools and new therapeutic targets, which can help to the development of innovative drugs, in a worldwide commercialization basis.
- Products >** Gendiag's current development status of the projects:
 CardioinCode®), DNA-Chip - cardiovascular risk Sudd inCode®) DNA-Chip will determine the risk to suffer sudden death. Trombo inCode® DNA-Chip for genotyping polymorphisms in genes involved in hereditary thrombophilia. Hemato inCode® DNA-Chip will determine the progression of chronic lymphocytic leukemia and assists in treatment selection.
- Interest areas >** GENDIAG creates alliances with investigators, research institutes, biotech and or pharmaceutical companies for the development of their project on a faster and efficient manner. GENDIAG wants to involucrate to the investigator in the development of the project and to share with him the benefits of the marketing when the idea turn into product.
- Contact >** tel.: +34 93 509 32 33 Margarita Garrido
<http://www.gendiag.com> margarita.garrido@gendiag.com



Genetrix, S.L.

- Mission >** Genetrix is one of a group of biotech companies specialised in the biomedicine area, born with the mission of fostering leading biopharmaceutical initiatives in the sector. The company's main objective is to incorporate the outcomes of academic research into Medicine.
- Services >** Genetrix is constantly working to bring together the outcomes arising from different scientific disciplines, by setting up and maintaining collaborations of a varied nature with public research centres, technological centres, public and private hospitals and pharmaceutical and biotech enterprises. This collaborative spirit is one of the features that most identifies the Genetrix Group's and its has proven to be of great value in making this ambitious business project a reality. The Group is working on the creation of biotech initiatives assessing, designing and executing business plans in the life sciences field.
- Interest areas >** Biotechnology. Life Sciences. Scientific applications for medical purposes. Investment in biotechnology
- | | | |
|---------------------|--|---|
| Contact > | tel.: +34 91 806 30 89
http://www.genetrix.es | Juan Sebastián Ruiz
jsruiz@genetrix.es |
|---------------------|--|---|



Genomica, S.A.U.

- Mission >** To offer experience and quality in all its products and services. To provide the health system with a tool for differential clinical molecular diagnosis applicable to infectious and oncogenic diseases. To be a reference centre in Spain for genetic identification tests, working under an accreditation frame provided by ENAC.
- Products >** Molecular diagnostic kits focused on infectious and oncogenic diseases.
- Services >** Human DNA identification tests. Forensic Genetics technology transfer by -Turn key projects-: design, assembling of the laboratory, training of personnel, technical service and population database creation. Using genomics and proteomics tools, systems are being prepared to detect therapeutic activity in marine organisms for different diseases.
- Interest areas >** In licensing: Oncology molecular diagnostic systems. New molecular diagnostic technologies. Out licensing: Technology transfer and training in forensic genetics.
- | | | |
|---------------------|---|---|
| Contact > | tel.: +34 916748990
http://www.genomica.es | Rosario Cospedal
rcospedal@genomica.es |
|---------------------|---|---|



Genzyme, S.L.

Mission >	The discovery and development of innovating products and services for the treatment of serious pathologies, with special attention to rare diseases. Genzyme S.L. is the subsidiary of Genzyme Corporation in Spain, dedicated to the development and introduction of therapeutic solutions for unresolved medical problems.	
Products >	Products on the market and under development at the following stages: Lysosomal diseases: Cerezyme®, Fabrazyme®, Aldurazyme®. Renal insufficiency: Renagel® Cancer: Thyrogen® Transplants: Thymoglobulina®. Immunological disorders Neurodegenerative diseases. Articular viscosupplementation: Synvisc®. Surgical adhesions: Seprafilm®. Biomaterials. Disease Pompe: Myozyme®	
Services >	Cell therapies	
Interest areas >	Rare diseases/ orphan medical products. Renal insufficiency. Oncology	
Contact >	tel.: +34 91 6591670 http://www.genzyme.com	Fernando Royo genzymespain@genzyme.com



GILEAD
Advancing Therapeutics.
Improving Lives.

Gilead Sciences, S.L.

Mission >	Investigate, Develop and commercialize innovative drugs in therapeutics areas with uncover needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.	
Products >	HIV: Viread® (tenofovir disoproxil), Emtriva® (emtricitabina), Truvada® (tenofovir disoproxil y emtricitabina) Hepatitis B: Hepsera® (adefovir dipivoxil) Antifúngicos: AmBisome® (anfoterina B liposomal)	
Interest areas >	Cardiovascular and Respiratory Area	
Contact >	tel.: +34 91 378 98 30 http://www.gilead.com	Roberto Urbez Plasencia roberto.urbez@gilead.com



Grifols Engineering S.A.

- Mission >** The company belongs to the Grifols holding and is specialized in engineering and consultancy services for the biotechnological and pharmaceutical fields. Grifols Engineering's objective is to become the appropriate collaborator for the scale-up of the biotech field companies, from development phases to industrial production.
- Products >** Services of Biopharmaceutical Engineering and Consultancy. Machinery for biotechnological process: Fermentation, purification and aseptic filling. Prototypes of machinery for biotechnological processes
- Interest areas >** Biotechnology. Technological applications for medical purposes
- Contact >** tel.: +34 93 571 03 93 Oriol Argemi
http://www.grifolsengineering.com oriol.argemi@grifols.com



Grupo Farmasierra

- Mission >** Pharmaceutical group of companies specialised in Research & Development, Manufacturing, Distribution and Marketing of Medicines, Food Supplements and Cosmetics operating at national and international level
- Products >** Gynaecology: Remifemin, Femiplante, Carbocal, Tricolam, Flucosil gel. Paediatrics: Calcio 20, Aminoveinte, Trofalgón, Trilombrin, Ibuprofeno. Urology: Prostulol. Generics: Acetilcisteína, Bisoprolol Farmasierra, Tramadol Farmasierra. Pain & Inflammation: Ibuprofeno Farmasierra, Tacrón, Astefer, Ibustick. Central Nervous System: Sinequan. Metabolism: Diabinese. Anti-infectives: Terramicina, Terra-Cortril, Fungo Farmasierra. Línea 20: Ferro 20, Sol 20, Derma 20, Multivitamínico Farmasierra. Food Supplements: Bifibran, Lactospore, Omega 3, Visdon, Omega 6, Resvecor, Nutrobal, Aceite de Onagra. Cosmetics
- Interest areas >** In terms of services GRUPO FARMASIERRA offers: Technological Development and High Tech Contract Manufacturing Services. Research & Development. Manufacturing of investigational Medicinal Products (IMP). Licences out. Licences in. Warehousing and Distribution Contract Services
- Contact >** tel.: +34 916 570 659 Tomás Olleros
http://www.farmasierra.com tomas@farmasierra.com



Grupo p-value

Mission >	Support biotechnology companies with their research and development programs, involved in the starting up and development of clinical research investigations through our technical and human means.	
Services >	We are a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, due to our wide experience in Clinical Research. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies, depending on the needs of our clients.	
Interest areas >	We are interested on collaborating on research and development projects with innovative medicines, or any other clinical research for all therapeutic areas	
Contact >	tel.: +34 902012292 http://www.grupop-value.com	Francisco Javier Navarro javiernavarro@grupop-value.com



Histocell, S.L.

Mission >	Histocell is a biotechnology company that offers to the bio sanitary sector innovative products based on human osteoblast, chondrocytes, keratinocytes, fibroblast and mesenchymal stem cells for tissue regeneration. These cell products will be applied to different pathologies in the regenerative medicine area. Histocell is also a research company involved in many R&D projects to develop an innovative pipeline of new health products for tissue engineering and cell therapy.	
Services >	Development of new biological drugs based on stem cells for human regenerative medicine. Tissue Engineering: Histocell has a Clean Room that allows to develop innovative products for clinical use in optimum quality conditions. Biological research services: cell amplification, cell metabolism, growth factors detection and cell cytometry, among other services. We also offer personalized tests to satisfy our customer needs. In vitro biocompatibility tests of materials for biomedical uses.	
Interest areas >	Histocell is a company with a great growth potential in next years. In next future, Histocell will open new research lines that solve the possible lacks existing in other regenerative medicine and cell therapy areas. Our company will also provide new cell/tissue products that will improve pharmaceutical and/or cosmetic testing of new cosmetics or new drugs. The company is interested in alliances with companies or research groups specialised in developing new biomaterials for tissue engineering.	
Contact >	tel.: +34 94 656 79 00 http://www.histocell.com	Marta Acilú acilu@histocell.com



Iden Biotechnology



Mission > Iden Biotechnology is a company with scientific profile whose main activity is the generation, development and exploitation of biotechnological knowledge. Iden Biotechnology is a technology transfer company matching market demands with biotechnology research interests from universities and technology centers.

Products > Iden Biotechnology develops biotechnological patents as its main product. The company also offers additional services as sub-contracted research projects, technical and financial project management, several biochemical analysis and Technology-Based Innovative Enterprises (EIBTs) creation advising.

Interest areas > Present and future areas of interest for Iden Biotechnology include the development of new raw materials suitable for biofuels industry, biomaterials industry, as well as molecules with industrial, pharmaceutical, agricultural and nutritional value

Contact >	tel.: +34 948152122 http://www.idenbiotechnology.com	Nora Alonso Nora.alonso@idenbiotechnology.com
---------------------	--	---



Igen Biotech, S.L.



Mission > Igen Biotech is a privately-owned firm focused on getting practical applications from advances made in medical research, turning them into products and leading them to the market. Company scope is focused on biomedicine, including new diagnostic kits for different diseases, pharmaceutical products and other therapies. Igen is currently developing agreements with other private firms and with public and private research centres to collaborate with them to jointly develop new R&D projects.

Products > Diagnostic kits.

Contact >	tel.: +34 91 510 29 99 http://www.igenbiotech.com	David Segarra d.segarra@igenbiotech.com
---------------------	---	---



Imbiosis, S.L.

Mission >	Imbiosis, S.L. is a spin-off company, founded out of the Gluten Unit of the National Centre for Biotechnology (CNB), in which Genetrix, S.L. holds a 100% shareholding. It was founded with the commitment to develop new forms of food diagnostics, to assure the celiac community the supply of the only effective treatment for their disease: gluten-free food products. Imbiosis S.L. has set itself the target of becoming a leading biotech company in the analysis and traceability of gluten in foodstuffs.	
Products >	Extraction Cocktail	
Services >	Quantitative techniques available: ELISA R5 Competitive ELISA R5. Qualitative techniques available: Western bolt. PCR RT. Malditof	
Interest areas >	Food diagnosis and traceability	
Contact >	tel.: +34 91 806 30 89 http://www.imbiosis.com	Juan Sebastián Ruiz jsruiz@genetrix.es



Immunostep, S. L

Mission >	IMMUNOSTEP is working day by day to achieve high quality products and services, to offer a new and proactive view to the search for solutions to the problem of cancer, producing reagents employed in diagnosis and research	
Products >	IMMUNOSTEP, S. L. has two divisions: Development, production and marketing tool for diagnosis of blood diseases by flow cytometry, IMMUNOSTEP Diagnostics. Development, production and marketing tool for research as well as providing services, IMMUNOSTEP Research.	
Interest areas >	In vitro and molecular diagnostics, Biotherapy	
Contact >	tel.: +34 923 29 48 27 http://www.immunostep.com	D. Ricardo Jara rjara@immunostep.com



Immunology and Applied Genetics, S.A. INGENASA

Mission >	Research, development, production and commercialisation of biotech products for animal health care.	
Products >	Serologic diagnosis assays. Molecular diagnosis assays. Second generation vaccines	
Services >	Protein expression, monoclonal antibodies	
Contact >	tel.: +34 913 680 501 http://www.ingenasa.es	Carmen Vela Olmo cvela@ingenasa.es



Infociencia

Mission >	Infociencia is a full-service clinical Contract Research Organisation (CRO) dedicated to the clinical drug development process of new molecular entities. We provide clinical trials from Phase I to Registration and Phase IV. Our mission is to deliver the highest level of quality, experience and care to the clinical trials of the Biotech, Diagnostics and Pharma Companies. Infociencia operates in Spain, and all over Europe and former Soviet Republics via its associate company IMITIS (www.imitis.com).	
Services >	We provide clinical operations in Spain and Europe for the development of the Clinical Trials Program of new drugs, from Phase I to Registration and Phase IV.	
Interest areas >	We can help Biotech and Diagnostic companies to conduct the clinical trials necessary for the product marketing authorization. We have experience in clinical trials, from the design of the clinical plan to the Phase I to Phase III, Registration, and Phase IV trials. We can help Biotech and Diagnostic companies to obtain the EMEA marketing authorization or the CE Marking. We can conduct clinical trials in all Europe and former Soviet Republics.	
Contact >	tel.: +34 932 15 80 08 http://www.infociencia.com	Jordi Naval Jordi.naval@infociencia.com



Ingredients Biotech S.L.U.

Mission >	Ingredients Biotech is a biotechnology company dedicated to the discovery and development of bioactive ingredients with effects on obesity, cardiovascular disease and diabetes, for functional food industries and dietetics.	
Products >	Discovery of Active Ingredients. Product Development. Nutrition and Health. Use of Byproduct	
Interest areas >	Discovery of bioactive compounds. Nutritional evaluation of bioactive compounds and functional foods. Developing products, processes and technology to food. Membrane separation technologies, microencapsulation, solubilization and controlled release of nutrients and bioactive compounds.	
Contact >	tel.: +34 958 750 985 / 628 735 741 http://www.ingredientsbiotech.es	Jesús Jiménez López jesusjimenez@ingredientsbiotech.es



Innofood I+D+I S.L.

Mission >	INNOFOOD I+D+I S.L. is a spin-off create to improve the research and technological development of the food industry through the benefit of services and projects of R&D to the industry and whose application will be as much to ingredients as to food products, obtaining with it the increase of the productiveness and quality, improves of the client competitiveness	
Services >	Assays and Improvement of food products shelf life. Design and development of new ingredients and foods. Special product design (functional, nutraceutical&). Conventional products redesign. Improvement of sensorial characteristics and commercialization. Application of new technologies to the elaboration of new foods (production systems, preservation, packaging...). Development of new functional and bio-ingredients from by-products	
Interest areas >	We offer the know-how in ingredients and products development and their application in different foods. Collaboration or joint-venture to work together in this field. Functional foods and functional ingredients. Projects about by-products from agrofood industry. Food biotechnology	
Contact >	tel.: +34 958 750 607 http://www.innofood-idi.com/	Jose Maria Fernandez Gines jmfernandez@innofood-idi.com



Institut Univ. de Ciència i Tecnologia, S.A. (IUCT)



Mission >	The mission of IUCT is to make use of its knowledge, expertise and capabilities to generate new technologies, products and processes for its industrial application in the Chemical, Pharmaceutical, Biotechnological and Environmental fields.	
Products >	IUCT has a large pipeline of products, processes and technologies available due to the development of its own R&D programmes to be transferred to the industry in the following areas: Drug Discovery, Industrial Biotechnology, Drug Development and Green Chemistry	
Services >	Research, Development and Innovation projects under contract (Contract Research). Technological services (Analysis and Consultancy). Transfer of knowledge and specialised training. Organization of seminars, workshops and congresses.	
Interest areas >	Pharmaceutical, biopharmaceutical and cosmetic sector. Chemical industry and fine chemical. Food industry. Environmental/ Health at work	
Contact >	tel.: +34 93 579.34.32 http://www.iuct.com	Angeles Molina luct.sales@iuct.com



Instituto Biomar, S.L.



Mission >	The discovery of new drugs of natural origin.	
Products >	Microbial marine extracts. Compounds of scientific or industrial interest, of microbial origin. Candidates to medicines in different phases of Development (Cancer, Anti-infection and SNC areas)	
Services >	Fermentation. Chemistry of natural products. Bioassays. Research programmes	
Interest areas >	Pharmaceutical and agrifoodstuff companies interested in the search for new bioactive principles of marine microbial origin. The company offers classified marine bacterial extracts, the undertaking of assays, fractioning, purification and structural elucidation of the active compounds. Production, up to kilos, of these for development studies.	
Contact >	tel.: +34 987 84 92 00 / +34 91 386 01 59 http://www.institutobiomar.com	Agustín Pérez-Aranda agustin@institutobiomar.com



Integromics, S.L.



Mission > To provide the market with up to date knowledge on IT solutions in the field of life sciences and particularly in genomics and proteomics.

Services > The development and marketing of software for genomic and proteomic data management, analysis and mining. Professional services relating to these products.

Interest areas > The development and commercialisation of software for genomics, proteomics and related sectors.

Contact >	tel.: +34 958 750 627 http://www.integromics.com	Vicente Rodríguez Vicente.rodriguez@integromics.com
---------------------	--	---



Intelligent
Pharma

Intelligent Pharma



Mission > Intelligent Pharma is a unique and innovative computational solution provider focused on drug design and target validation. Intelligent Pharma develops customized and highly-specialized computational solutions for our clients in order to reduce their costs, time and/or risks in their molecular research projects.

Products > In early research stages we offer the following areas of expertise: Computer-aided drug design. Molecular modeling. Virtual screening. Compound library management and intelligent accessory tools. ADME/Tox modeling. Knowledge extraction and data mining from chemical and biologic databases. Biologic image processing. Improved/enhanced supercomputational research infrastructure

Interest areas > Drug discovery

Contact >	tel.: +34 934 034 551 http://www.intelligentpharma.com	Ignasi Belda ibelda@intelligentpharma.com
---------------------	--	--



Juste, S.A.Q.F.

Mission >	JUSTE, S.A.Q.F. is a company which researches, develops and distributes pharmaceutical products. JUSTE also has an outstanding R+D and industrial activity related to the generation and manufacture of soft-gel capsules.	
Products >	The Therapeutics Division commercializes prescription drugs for the three following Areas: Primary Care, Women's Health Care and Central Nervous System. The Hospital Division remains dedicated to the diagnosis within the radiology field. JUSTE has diversified its hospital diagnosis line taking part and acquiring new projects and products which incorporate innovative technologies on diagnosis, oncology and anesthesia.	
Interest areas >	JUSTE maintains a continual interest in collaborating on development projects as well in establishing License agreements (exclusive licenses, co-marketing and/or co-promotion agreements) for Spain, Portugal, Central America and South America countries in the following therapeutic areas Primary Care, Women's Health Care and Central Nervous System and products for diagnosis and treatment aimed at hospitals. JUSTE is aware of the advances in biotechnology and considers very important the use of genetics for a personalized medicine. JUSTE commits itself in the innovative biotechnology industry with new products for clinical diagnosis.	
Contact >	tel.: +34 91 724 82 00 http://www.juste.com	Charo Guinea roguinea@juste.net



Labgenetics, S.L.

Mission >	To carry out highly accurate and decisive genetic tests within a minimum response period. To apply the most advanced techniques to identify alterations in the DNA sequence related to the onset of the most prevalent hereditary diseases in Europe. To consolidate as the Reference Centre in Forensic Genetics and Human Genetic Identification Tests.	
Products >	Forensic Genetics: Paternity testing, parentage (kinship) analysis and genetic identification (DNA fingerprinting) from any biological traces. Clinical Genetics: Molecular Diagnostics of more than 250 hereditary diseases. Technology Transfer: Set up and start up of Molecular Biology -turn-key- laboratories, focused on human genetic analysis. Scientific Advisory Services: Interpretation of expert reports based on DNA evidences in civil legal and penal procedures.	
Interest areas >	Development of new Molecular Diagnostic techniques. Projects of Forensic Genetics and Genetic Diagnostic training. Development and distribution of new Molecular Diagnostic Kits.	
Contact >	tel.: +34 916592298 http://www.labgenetics.com.es	Jorge Puente Prieto jorge.puente@labgenetics.com.es



Laboratorios Calier, S.A.

Mission >	Research, development and commercialisation of veterinary products aimed at production animals, together with specialised products aimed at pets and a select range for horses. A company producing raw materials and finished products for the Animal Healthcare market, our activity comprises the research, development, production and commercialisation in 70 countries of generic products, licences and its own know-how, including those lying in the immunological, pharmacological, nutritional and biocide fields. The two vertical biotechnology lines are the extraction and purification of matrix proteins and biological fluids and the production and extraction of heterologous proteins of immunological or pharmaceutical interest. Both lines are oriented towards obtaining hormone and immunological products.	
Products >	Pharmacological pharmaceutical specialities. Immunological pharmaceutical specialities. Animal care, hygiene and handling products. Biocides. Animal food additives	
Services >	Autovaccines, diagnostics and eradication programmes.	
Interest areas >	General immunology. Animal reproduction. Expression systems of heterologous recombinant proteins.	
Contact >	tel.: +34 93 506 91 00 http://www.calier.es	Joan Marca y Puig jmarca@calier.es



Laboratorios LETI, S.L.

Mission >	Human Health Care / Therapy. A pharmaceutical laboratory specialised in immunology and preventive medicine, diagnostic products and self-health care.	
Products >	Allergy: Diagnoses, allergen extracts for treatment, bacterial treatments, environment control, allergens. Diagnostics: Fast and molecular biology diagnostics for infectious diseases. Personal care: LETI AT-4, Urea LETI, Sebamed, Letibalm, Letitest, etc. Vaccines: Antitetanus; Anti Diptheria-tetanus-pertussis DTP; LETI polyspecific influenza vaccine. Veterinary Diagnosis: LetQTest	
Contact >	tel.: +34 933 945 350 http://www.leti.com	Gloria Roé groe@leti.com



Laboratorios Ovejero, S.A.

Mission > The development, manufacturing and commercialisation of pharmaceutical and veterinary products.

Products > Contract Manufacturing

Interest areas > Development of Immunological Products

Contact >	tel.: +34 902 235 700 http://www.labovejero.com	Juan Pablo Ovejero Gerencia@labovejero.es
---------------------	--	--



Laboratoris Sanifit, S.L.

Mission > Laboratoris Sanifit is a biotechnology company dedicated to the research and development of health products and to transferring this research for the benefit of society. Sanifit's work focuses on research and development of innovative drugs and products for the treatment and/or prevention of diseases, mainly in the cardiovascular and renal fields.

Services > SNF-471: drug in preclinical phase indicated for the prevention of cardiovascular calcifications. SNF-571: drug in preclinical phase indicated for the prevention of calcic renal lithiasis. Patents granted.

Interest areas > Drugs and other products in the following areas: Urology. Cardiology. Dermatology. R+D of new drugs

Contact >	tel.: +34 871 70 30 62 http://www.sanifit.com	Bernat Isern Amengual laboratoris@sanifit.com
---------------------	---	---



Laimat, Scientific Technical Solutions, S.L.



Mission >	Providing scientific technical solutions to the industry which develops new highly competitive materials in the pharmaceutical, agro-food, polymers, ceramics and pigments sector. Integral research and development service which covers the technologic necessities in the sector of these materials.	
Products >	Applied research. I+D+I projects according to the customer. Technology and knowledge management. Analyze and characterizations. Continue formation and legal advice. We are specialist in the development of projects based in the Physics- Chemistry of the materials in solid and liquid state. Science and nanotechnology particles, Biomaterial solid state. Polymorphism in drugs. Thermodynamic stability. Coating and microencapsulated. Physical-chemical characterizations	
Interest areas >	Bio-technologic sector. Pharmaceutical sector, drug discovery, development and processes of new drugs. Agro-food sector. Research and development of new biomaterials: biopolymers, ceramics.	
Contact >	tel.: +34 958 750 951 / 858 100 141 http://www.laimat.com	Josefina Pedrajas fpedrajas@laimat.com



Lipopharma



Mission >	Lipopharma is a biotech company aimed at the discovery, design and initial clinical development of new medicines aimed to be used in human pathologies over the basis of the Membrane Lipid Therapy (MLT). Our initial objective is to complete Minerval's Phases I and II of clinical trials for Lung Cancer and Glioma.	
Products >	Minerval, the first molecule to be developed, combines a powerful anti cancer effect with an absence of toxicology or side effects. Lipopharma is also developing a portfolio of new products based on the MLT with potential applications in fields such as neurodegenerative diseases, cardiovascular pathologies or cancer.	
Interest areas >	Lipopharma would be interested in collaboration agreements with other companies / research groups specialized in the field of membrane lipid's interactions. Lipopharma will also seek alliances with large multinational pharmaceutical companies who can bring in the technical and financial muscle needed to complete last phases of clinical trials, register and eventually commercialize the products worldwide.	
Contact >	tel.: +34 971 439 886 http://www.lipopharma.com	Vicenç Tur v.tur@lipopharma.com



Business Members



Lonza Biologics Porriño, S.L.

Mission >	Produce recombinant monoclonal antibodies from mammalian cell culture.	
Products >	Cell culture and recombinant monoclonal antibodies	
Contact >	tel.: +34 986 344 060 http://www.lonza.com	Manuel López cristina.alonso@lonza.com



Merck Farma y Química S.L.

Mission >	Research and development, production and commercialization of products of high quality in the pharmaceutical and chemical sectors. We focus our activities on businesses where we achieve competitive advantages thanks to the innovation of our products, services and systems. We guarantee that our objectives are fulfilled by developing company policies and practices that are responsible with the society and the environment.	
Products >	Pharma: Merck Serono: includes innovative leading prescription drugs, for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular and metabolic disorders and psoriasis. Consumer Health Care: includes a wide range of well-known over-the-counter drugs for everyday health. Chemical: Liquid crystals: leading manufacturer for LCD displays. Pigments: effect pigments for the automobile industry, plastics, coating; pigments and other substances for the cosmetic industry. Reagents and test kits: inorganic high quality reagents, organic chemical products, laboratory tests, among others. Life Science Products: Excipients, active principles and other materials for the pharmaceutical and biotech industry.	
Contact >	tel.: +34 935 655 500 http://www.merck.es tel.: +34 91 745 44 00 http://www.merckserono.net	Laura González-Molero comunicacion@merck.es

**MSD**El lado humano de la medicina
www.msd.es**Merck, Sharp & Dohme de España, S.A.****Mission >** The research, development, commercialisation and manufacturing of innovating medicines.**Products >** Medicines**Interest areas >** New medicines development in the selected therapeutic area. New therapeutic target research

Contact >	tel.: +34 91.321.06.78 http://www.msd.es	Regina Revilla regina_revilla@merck.com
---------------------	---	--

**Microbionta****Mission >** Application of our technologies of expression and selection of recombinant antibodies in bacteria to the development of new therapeutic antibodies.**Products >** Technological platform for the selection of antibodies in bacteria by bacterial display. Specific antibodies as therapeutic agents for inflammation, cancer and infectious diseases.**Interest areas >** New targets involved in inflammation, cancer and infectious diseases, for the selection of new antibodies.

Contact >	tel.: +34 91 141 7150 http:// www.microbionta.com	Myriam de Grado mdegrado@microbionta.com
---------------------	---	---

**Miltenyi Biotec****Mission >** Miltenyi Biotec develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications.**Products >** MACS® Technology for Cell Separation. AutoMACS™ CliniMACS®. Microarrays & Bioinformatics. Adsorbers for Therapeutic Apheresis.

Contact >	tel.: +34 915121290 http://www.miltenyibiotec.com	Iván Alvarez-Sierra macs@miltenyibiotec.es
---------------------	--	---



Monsanto Agricultura España, S.L.

Mission > To attend the world's food needs. To conserve natural resources. To protect the environment. To serve our customers and our shareholders.

Products > Monsanto is a group of companies whose activity is aimed at the development and improvement of agriculture and the food sector. For over one hundred years Monsanto has been researching, developing and commercialising services for the farming sector and it has concentrated its aims on providing sustainable agricultural systems, beneficial for farmers all over the world.

Monsanto is committed to developing safe technologies and products that are beneficial for both farmers and consumers.

Our most outstanding products are our herbicides from the Roundup range and the Dekalb brand seeds. For further information on our products go to: <http://monsanto.es/monsanto-toes/productos.html>

Interest areas > Plant Biotechnology. Conservation farming. Biofuels.

Contact > tel.: +34 913 432 701
<http://www.monsanto.es>

Rosa Moreno
rosa.m.moreno@monsanto.com



Natraceutical Group

Mission > To lead the global functional food sector by developing and manufacturing healthy ingredients and services to help our customers achieve optimal performance in the marketplace.

Products > Natraceutical specialises in the research, development and commercialisation of functional ingredients and health imbuing natural compounds aimed at the food, cosmetics and pharmacy sectors.

Obipektin, production of natural pectins, together with fruit and vegetable powders. Its tomato powder, Sprea Ô type 707, is considered to be the market standard for the highest quality.

Overseal Natural Ingredients natural colourants and colouring foodstuffs, active dry yeast, the HinotesÔ aromas and Talin (Thaumatococcus).

Beta-glucan (Viscofiber®) provides one of the most convenient and beneficial kinds of fibre.

Interest areas > Innovation and development of functional ingredients for the food, cosmetics and pharmacy sectors.

Contact > tel.: +34 961 920 851
<http://www.natraceuticalgroup.com>

Zachary Sniderman
info@natraceuticals.com



Neocodex, S.L.

Mission >	NeoCodex is a biomedical and genomic research company focused on understanding the molecular and genetic basis of human disease.	
Products >	Successful in engineering and housing Spain's largest databank of DNA samples, NeoCodex has created a nationwide cooperative of hospital systems, working together to build a fully-annotated network of samples from common disease states present within the uniquely homogenous population of Spain (www.neocodex.com).	
Interest areas >	HFCC presents clients with a revolutionary new way of conducting whole genome association studies. Used as a prioritization tool, the strategy behind HFCC allows for the use of different, but related, phenotype analysis in the same study, making use of multi-locus analysis instead of the marker-by-marker approach	
Contact >	tel.: +34 955047618 http://www.neocodex.com	Rocío Pascual rpascual@neocodex.es



Neuron BPh

Mission >	NEURON BPh is a private biotech Company focused on the discovery and product development of biomolecules for the prevention and early treatment of neuro-degenerative diseases, mainly Alzheimer disease using our patented technology: "hAPPy Mouse", the only transgenic mouse model that contains the genomic form of the human APP gene.	
Products >	Development and Optimization of bioprocesses. Screening of molecules with neuroprotective activity. General Toxicity studies. Organ specific toxicity (mainly neurotoxicity). Pharmacokinetic & pharmacodynamic (ADME/tox studies).	
Interest areas >	NEURON BPh is always open to incorporate innovative technologies in the fields of the Neurobiology, Microbial Biotechnology and the Natural Product's Chemistry.	
Contact >	tel.: +34 958 750 598 http://www.neuronbp.com	Javier Velasco info@neuronbp.com



Neuroscience Technologies, S.L.

Mission >	Research on the mechanisms of neuropathic pain. Development of new therapeutic drugs.	
Products >	New drugs for neuropathic pain treatment	
Services >	Studies on patients with neuropathic pain. Studies on experimental models of axonal hyperexcitability.	
Interest areas >	Development of new drugs targeting axonal hyperexcitability. Development of diagnostic devices for neuropathic pain.	
Contact >	tel.: +34 93 402 0164 http://www.nsc-tec.com	Dra. Cristina Quiles cquiles@nsc-tec.com



Newbiotechnic, S.A.

Mission >	To identify, protect and commercialise microbiological and molecular tools with an immediate, practical application in the farming and agrifoodstuffs sector, which are safer for the consumer and more respectful with the environment. Founded in 1999, NBT is an R&D company in farming and agrifoodstuff biotechnology, with three business areas: 1) Biological control agents 2) Gene technology for improving crops and 3) Molecular diagnostics services	
Products >	Biological Control Agents (biofungicides, bioinsecticides). Tools for plant improvement by genetic transformation.	
Services >	Genomic and Bio-IT services. Phytopathological diagnostics. Agrifoodstuff diagnostics. Veterinary diagnostics. Human genetic diagnostics	
Interest areas >	The development of microbiological products for crop protection. Submerged fermentation technology and product recuperation. Co-development/ distribution of natural products for agriculture (microbiological products, plant extracts, organic extracts, etc.). Development of diagnostic genetic tests for farming, aquaculture, veterinary and food product applications. The development of concept tests in plant genetic transformation.	
Contact >	tel.: +34 955 776 710 http://www.newbiotechnic.com	Manuel Rey mrey@nbt.com



Noray Bioinformatics, S.L.U.



Mission > NorayBio is a company that supports the life sciences industry: biotechnology, biomedicine and biopharmacy by developing new solutions report Ticas. NorayBio offers advanced software for data acquisition, analysis and management information generated by biociencias. Nuestras software solutions are specifically geared to enable the handling of large amounts of information generated in biotechnology research and understanding of the biological significance of the data obtained.

Products > NorayBio divided into four product lines: Biopharmacy (Software Noraymet ADME, software Noraymet bioEquiv), Systems Biology (Histomass, bioinformatics platform NorayLiver and Web portal NoraySB), Integration (software BioLIMS and Web platform ServiLIMS), Biological Data Management (software AniBio, software AniBio Aquatic, software Fivisoft and software NorayBanks)

Interest areas > Metabolomics, pharmacogenomics, neurogenomics

Contact >	tel.: +34 944 036 998 http://www.noraybio.com	Julio Font font@noraybio.com
---------------------	--	--



Noray Biosciences Group (Noray BG)



Mission > Noray Biosciences Group, founded in December 2006, is a holding Group focussed on Biosciences, situated among the ten first companies of the Spanish Biotechnology sector. The Group is composed by two companies at this moment: Histocell and NorayBio. Its mission is to manage and integrate the companies in the Biosciences sector to enhance their access to the market and their internationalization. Noray BG stands out for its innovation management model, based on efficiency and search of solutions for the real needs of the Biotechnology sector.

Services > Noray BG is a holding dedicated to the management of its companies (NorayBio and Histocell, at the moment), in different fields like strategic management, business development, internationalization, financial management and human resources.

Interest areas > Noray BG's strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms. Everything done with the firm idea of motivating the expansion throughout the European and international market, making the most out of the synergies among the Group companies.

Contact >	tel.: +34 94 403 69 98 http://www.noraybg.com	Julio Font font@noraybio.com
---------------------	---	--



Noscira

Mission >	The development of medicines for the treatment of diseases of the CNS.	
Products >	Molecules under research against neurodegenerative diseases, mainly Alzheimer's Disease. Two composed in Phase I of clinical development: NP-12 and NP-61; various composed in previous phases.	
Interest areas >	Within our collaborations policy, Noscira maintains relations with numerous public and private sector research institutions, to advance in the development of our molecules and for the research into new ones against neurodegenerative diseases. The company is interested in setting up new collaborations with research centres that will lead to an enhancement of our activities in the field of neurosciences.	
Contact >	tel.: +34 918061130 http://www.noscira.com	Mercedes Rodríguez Barrera mrodriguez@noscira.com



Omnia Molecular, S.L.

Mission >	Omnia Molecular Ltd. (Omnia) is a biotech start-up, focused on the development of a new strategy for the discovery of active molecules with applications as antibiotics, antifungals, or anti-parasitary drugs. Omnia owns exclusive rights to patented technology developed at the Barcelona Institute for Research in Biomedicine.	
Products >	Omnia's technology applies a completely new approach to the selection of pharmacological lead compounds, based on a cellular assay that simultaneously screens compounds for several pharmacological parameters, thus accelerating and improving current methods for the discovery of anti-infective drugs. Our screens are directed against a validated target of universal distribution and they can be used to identify lead compounds against any cellular pathogen.	
Interest areas >	We are currently focused on the development of new molecules against three human infections: pneumonia caused by <i>Streptococcus pneumoniae</i> , gastric ulcer caused by <i>Helicobacter pylori</i> , and multi-resistant mycosis caused by <i>Aspergillus fumigatus</i> .	
Contact >	tel.: +34 934 020 158 http://www.omniamol.com	Lourdes Saltó lsalto@omniamol.com



Operon, S.A.

Mission >	To be international leader in 6 technologies relating to In Vitro Diagnosis: Monoclonal antibodies, recombinant antigens, agglutination latex, immunochromotography, ELISA and Molecular Biology tests.	
Services >	Research, development and manufacturing of Monoclonal Antibodies and Recombinant Antigens. RD&I and manufacturing of In Vitro Diagnostic kits based on immunological reactions and molecular biology	
Interest areas >	Industrial production and purification of monoclonal antibodies and recombinant antigens. Design and large scale production or with own brand of new In Vitro Diagnostic tests.	
Contact >	tel.: +34 976 503597 http://www.operon.es	Tomás Toribio Info@operon.es



Oryzon Genomics

Mission >	Oryzon is a biomarker discovery company with a Diagnostic and Therapeutic pipeline focused in Oncology and Neurological disorders. Oryzon's mission is the identification of gene functions and proteins so as to design and develop biotechnological products that improve people's health.	
Services >	The company has an integrated bio-marker discovery and validation platform and develops its own core research program, with an increasing number of projects in selected niches of the biomedicine area always in partnership with the Academia and Pharmaceutical companies.	
Interest areas >	Oryzon has several important strategic alliances with food, biotech and pharmaceutical companies and is looking for industrial pharma and food partners to launch new global projects.	
Contact >	tel.: +34 934 037 196 http://www.oryzon.com	Vanessa Arroyo varroyo@oryzon.com



Palau Pharma

Mission >	To discover and develop alone or in collaboration with our strategic partners novel, patent-protected pharmaceuticals for the treatment of inflammatory or autoimmune conditions	
Products >	Our projects under internal development are: Dersalazine sodium: Anti-inflammatory agent, Phase II Development Project 1 (DP-1). Phase I. Discovery Project 1 (DD-1). Discovery Project 2 (DD-2). The projects developed by our partners are: Albaconazole: Oral and topical anti-fungal agent (partner: Stiefel Laboratories). p38 MAP kinase inhibitor: Anti-inflammatory agent (partner: Schering Plough). Cimicoxib: Cyclooxygenase-2 inhibitor for veterinary use (partner not disclosed). Triflusal-Stents: Drug eluting coronary stent coated with a polymer containing the drugs triflusal and simvastatin (partner: Iberhospitex). Cimicoxib: depression (partner: Affectis Pharmaceuticals).	
Interest areas >	In-licensing: We are eager to establish collaborations with companies interested in out-licensing their patent protected New Chemical Entities. We are specially interested in compounds that have reached the late preclinical stage or early Phase I clinical trials (diseases of allergic and autoimmune origin, such as psoriasis, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease and others). Out-licensing: Out-licensing after having completed at least one Phase II clinical trial (proof-of-concept) forms the core of our business strategy.	
Contact >	tel.: +34 93 864 96 92 http://www.palaupharma.com	Lydia Sanmartí Vila lsanmarti@palaupharma.com



Pevesa, S.L.

Mission >	To be a reference in the design, production and R&D in the area of proteins, peptics and amino-acids and biochemical compounds employing biotechnology as a work tool.	
Products >	Proteins, peptics, biochemical products.	
Services >	Industrial Biotechnology and Biochemical Engineering. Enzyme and Fermentation Technology. RD&I Laboratories and Pilot plant	
Interest areas >	Contract manufacturing, custom made manufacturing. Product development. Collaboration, research and development agreements for new products. Joint Ventures. Investment in biotech projects	
Contact >	tel.: +34 955 946 024 http://www.pevesa.es	Iñaki Mielgo imielgo@pevesa.es



Pharmakine

Mission >	To develop products and services that foster advances in the research, diagnosis and treatment of cancer and metastasis.	
Products >	Organ-specific primary cultures, tissue arrays, cell-arrays, conditioned media, tumor spheroids.	
Services >	Preclinical evaluation of compounds with anti-tumor, anti-angiogenic or anti-metastatic activity. Oncology diagnosis support services: progression tumor markers, subclinical tumor dissemination and personalized therapy. Specialized histology services.	
Interest areas >	Development of novel anti-tumor or anti-metastatic compounds. Development of cell-based assays for preclinical evaluation of drugs. Development of advanced diagnostic systems for the early detection of metastasis. Development of advanced prognostic methods for cancer patients	
Contact >	tel.: +34 944317037 http://www.pharmakine.com	Lorea Mendoza lmendoza@pharmakine.com



Pharmamar, S.A.U.

Mission >	PharmaMar is a biopharmaceutical company devoted to advance cancer care through the discovery, development and commercialization of innovative marine-derived medicines.	
Products >	Yondelis®: European Marketing Authorization (MAA) granted in July 2007 for Soft Tissue Sarcoma. The MAA for the second indication of Yondelis®, ovarian cancer, will be filled to the EMEA in 2008 and Phase II clinical trials are ongoing in Prostate and Breast cancers. Aplidin®: Positive Phase II data in heavily pre-treated, relapsed/refractory Multiple Myeloma. Orphan Drug designation by the EMEA and the FDA for Acute Lymphoblastic Leukaemia and Multiple Myeloma. Kahalalide F: Promising clinical results from exploratory Phase II trial in severe psoriasis. Zalypsis: Phase I trials in solid tumors ongoing.	
Interest areas >	Our business strategy relies in maintaining a strong pipeline of products in development. For the drugs in our Oncology pipeline, we seek partners for development and commercialization outside of Europe. As well, PharmaMar is interested in licence-in Phase III or commercialize stage products in oncology haematology malignancies, to maximise our specialised commercial organization established in Europe.	
Contact >	tel.: +34 91 846 6000 http://www.pharmamar.com	Ana Benavides abenavides@pharmamar.com



Pioneer Hi-Bred Spain, S.L.

- Mission >** The development, production and commercialisation of agricultural seeds and inoculants for the conservation of animal fodder.
- Products >** Maize, Sorghum, sunflower, cotton, soybean, corn, lucerne, rape seeds. Lactic bacteria inoculants for animal fodder conservation
- Services >** Comprehensive agronomic services of complete advisory service to agricultural users of the plant species marketed.
- Interest areas >** The development of varieties of plant species and inoculants for agriculture and stock farming. Development of methods and knowledge concerning stock feeding. Development of varieties of plant species for human nutritional use. Development of varieties and processes for the bio-energy industry. Development of processes for improving and knowing the agricultural crop environment better (soils, waters, efficiency and irrigation methods, abiotic factors, pest control, etc.)
- Contact >**

tel.: +34 954 298 300 http://www.pioneer.com	Alberto Ojembarrena Alberto.Ojembarrena@pioneer.com
--	---



Probelte

- Contact >**

tel.: +34 968 307 250 http://www.probelte.es/	Sergio Streitenberger streiten@probelte.es
--	---



Proteomika, SL

Mission > In vitro diagnostic product development. Non-invasive biomarker discovery. New biomarker validation techniques. To provide the healthcare community with new tools in personalized medicine.

Products > IVD Kits in cancer and related pathologies. New serotyping tests and technologies. Therapeutic targets. Proteomic and cytomic services.

Interest areas > Proteomika actively seeks for industrial and institutional partners in the area of biosciences for the development of in vitro diagnostic products based on non-invasive protein biomarker detection and quantification. Collaborations with biotech companies in the fields of multiplexing platforms and instruments, immunology, microfluidics, and new high throughput biomarker discovery techniques are valued. Collaborations with applied research institutions and pharma companies committed to the development of biotechnological products in the area of interest of Proteomika.

Contact >	tel.: +34 944 064 525 http://www.proteomika.com	Juan Pedro López Araguás plaraguas@proteomika.com
---------------------	--	--



Proyecto de biomedicina CIMA, SL (BITA)

Mission > Managing, patenting and exploiting all the results coming out from the research activity carried out in the "CIMA project" a joint venture between a group of several first class spanish companies and the "CIMA" (Research center for applied medicine owned) by the "University of Navarra"

Products > See the web www.proyectobiocima.com

Interest areas > Licensing for the development of the results owned by the company, through licensing agreements with biotech companies or by setting up new companies to develop these results

Contact >	tel.: +34 948287561 http://www.proyectobiocima.com	Antonio Martin amartin@proyectobiocima.com
---------------------	--	--



Puleva Biotech Exxentia

Mission > Convert ourselves into a reference for our clients in product development based on natural extracts, lipids and probiotics

Products > Vegetable, lipid and probiotic extracts. Exclusive product development. Technical and legal consultants. Regulatory affairs. Stability studies

Interest areas > Development of new bio active ingredients based on vegetable, lipid and probiotics extracts and their application in the pharmaceutical, food and cosmetic industries.

Contact > tel.: +34 91 380 29 73
http://www.exxentia.com

José Carlos Quintela
jcquintela@exxentia.com



Roche Applied Science

Mission > Roche Applied Science provides superior bioanalytical solutions for the life science market", the business areas offers integrated solutions for research applications, including all experimental steps that lead from sample to results

Products > With more than 2000 products for: Genomics : Instruments and reagents for qPCR , nucleic acid extraction and analysys, pirosequencing and microarrays. Proteomics reagents and cellular analysis. Raw materials and industrial GMP Grade products, contract manufacturing and customized/dedicated products

Contact > tel.: +34 935 83 40 00
http://www.roche-as.es
http://www.roche-applied-science.com

Carlos Manchado-Perdiguero
/ Neus Diez May
carlos.manchado-perdiguero@roche.com;
neus.diez@roche.com



Schering-Plough

Schering-Plough

Mission > Schering-plough is a global pharmaceutical company with more than 50,000 people in more than 125 countries around the world. The company vision is to earn the trust of doctors, patients and customers as a company that provides them with science-based medicines and services.

Products > With the recent combination with Organon in November 2007, the company offers now products in 6 therapeutic areas: cardiovascular disease, central nervous system, immunology and infectious disease, oncology, respiratory and women's health. Moreover, the company has a great pipeline with several products in phase 2 or phase 3 development.

Interest areas > Schering-plough activity is based in 6 therapeutic areas with interests in: cardiovascular disease, neuroscience, anesthesia, immunology (rheumatoid arthritis, crohn disease, psoriasis), infectious disease (hepatitis c and hiv), oncology, respiratory (asthma and allergy) and women's health (gynecology and fertility)

Contact > tel.: +34 91 567 31 64
<http://www.schering-plough.es>

Fernando García Alonso
fernando.garcia.alonso@spcorp.com



Seaweed Canarias

Mission > To develop and supply our customers with all-round, sustainable, advanced technology solutions, through the industrial application of active principles from macro and microalgae

Products > AlgaCanTM: A range of organic biostimulants for agriculture, based on a unique combination of macro and microalgae. AlgaCan products are biotechnology solutions to promote growth and quality production and to protect and prevent plants from diseases and plagues. Added value additives for human and animal nutrition: compounds enriched with natural ingredients exclusive to seaweeds. Cosmetic products based on active principles from seaweeds such as antioxidants and skin firming products.

Services > Personal technical assistance to guarantee the best application methodology

Interest areas > Innovation and development of innovating added value additives for nutrition: products that contain nutritional elements and properties exclusive to seaweeds. International distribution of ALGACAN range of products.

Contact > tel.: +34 928 18 43 55
<http://www.seaweedcanarias.com>

Sergio Cáceres
scaceres@seaweedcanarias.com



Sensia, S.L.



Mission > Sensia is the first Spanish Initiative to set up a leading company in the instrumentation sector for life science research laboratories and for environment measurement. Sensia develops and commercialises portable, multibiosensor systems, based on technologies developed by the Biosensors Group of the National Microelectronics Centre, belonging to the Higher Council for Scientific Research.

Products > SENSIA 2-SPR is an instrument based on Surface Plasmon Resonance (SPR) which enables comparative measurements to be made by incorporating channels. It also includes computer-controlled pumps and microfluid valves for sample injection. The Surface Plasmon resonance is a powerful technology for measuring biomolecular interactions, allowing real-time measurements without having to brand the analytes. The 2-SPR system has a large number of applications; in general all those studies based on biomolecular interactions: biochemical and chemical detection, discovery of medicines, diagnostics, proteomics, genomics, forensic medicine, food analysis, environmental monitoring, etc.

Interest areas > The development of biosensors and their components. The development of new biosensor applications. Basic and clinical research. Diagnostic applications

Contact >	tel.: +34 91 806 30 89 http://www.sensia.es	Juan Sebastián Ruiz jsruiz@genetrix.es
---------------------	--	---



Sigma Aldrich Química, S.A.



Mission > We are committed to our customers, employees and shareholders success through science, technology and service.

Products > Reagents, chemical and biological products, laboratory kits and supplies for scientific life science research, biotechnology and high technology chemistry and for pharmaceutical and chemical development and manufacturing.

Services > Customised development and synthesis of chemical and biological products, scale increases.

Contact >	tel.: +34 900101376 http://www.sigma-aldrich.com	Javier Márquez jmarquez@europe.sial.com
---------------------	---	--



Sistemas Genómicos, S.L.



Mission > Our main activity is research, development and commercialization of analytical applications based on genomics technology. We provided high added value services and products, as well as customized R&D projects addressed to Food analysis, Human Health, Biopharmaceutical and Genomic Research.

Products > SG Food Analysis: GMO Analysis. Food Allergens Detection. Genetic Authentication in Food. Rapid Pathogen Detection. Genomic Identification and Typing. Water Analysis. Molecular Analysis Kits
SG Human Health: Genetic Counseling. Genetic Diagnostics. Prenatal Genetic Diagnostics. Rare Diseases. Molecular Oncology. Genetics in Oncohematology. Preimplantation Genetic Diagnosis (PGD). Molecular Diagnosis Sets
SG Research: DNA Sequencing. Ultrahigh throughput Sequencing Projects Bioinformatics.

Interest areas > Our company actively seeks the establishment of strategic alliances to promote R-D projects in Genomics. In 2008 the company has purchased the Ultrahigh Throughput Sequencing highest technology equipment available in the market: SOLID platform. And it allows us to collaborate and offering this new and exclusive technology to the whole scientific community.

Contact >	tel.: +34 902 364 669 http://www.sistemasgenomicos.com	Lucía Pérez Navarro lucia.perez@sistemasgenomicos.com
---------------------	--	---



Soluciones Extractivas Alimentarias, S.L. (SOLUTEX)



Mission > Be the world-leading company in the production of ingredients by supercritical CO2 technologies for the pharmaceutical, cosmetic, nutritional, food and beverage industries.

Products > EPA (Eicosapentaenoic Acid) until 95%. DHA (Docosahexaenoic Acid) until 85%. SDA (Stearidonic Acid) until 50%. Omega-3 PUFAS until 95%. Lycopene until 50%. Terpeneless Citrus Oils in the desired folding. Sesquiterpeneless Citrus Oils in the desired folding. Terpenes. Sesquiterpenes. Magnetic Nanoparticles

Interest areas > We look for partners interested in collaborating in clinical studies with products containing our ingredients. We also are interested in partnering with companies with complementary technologies with ours, in order to increase competitiveness or technological development. Of course we are always interested in establishing commercial relationships with first movers in every region/sector.

Contact >	tel.: +34 91 806 04 77 http://www.solutex.us tel.: +1 312 794 7882 http://www.solutex.es	Fernando G. Santos fgsantos@solutex.es
---------------------	---	--



Business Members



Suanfarma Biotech S.G.E.C.R. S.A.

Mission > We are the first venture capital asset management company specialized in biotechnology to be authorized by the Spanish CNMV (equivalent to US SEC). We support our participated companies in several different areas, such as business and commercial activities, industrial and R&D support, as well as regulatory guidance and financial advice.

Services > Our first fund Suan Biotech FCR received CNMV approval in September 07, and it is authorised to raise up to 30 million euros (closing by Sept-08). The current portfolio of investments already managed by Suanfarma Biotech SGEGR SA includes five companies: Orphamed, 3P Biopharmaceuticals, Pevesa, Halotech, and Clave Suan

Interest areas > SUANFARMA BIOTECH SGEGR, S.A. evaluates investment opportunities with a strong and solid science, IP and growth potential. We look for projects and opportunities within universities, tech transfer units, R&D centers and within our national biotech and pharmaceutical market

Contact >	tel.: +34 91 571 35 98 http://www.suanfarmabiotech.com	Gonzalo Marin gonzalomarin@suanfarma.com
---------------------	---	---



Sylentis, S.A.U.

Mission > Biotech and therapeutic applications in interference RNA technology

Interest areas > RNA interference (RNAi). Animals models. Toxicity essay. Drug delivery

Contact >	tel.: +34 918234553 http://www.sylentis.com	Ana Isabel Jiménez aajimenez@sylentis.com
---------------------	--	--



Telstar Projects, S.A.

Mission >	Company specializing in design, supply, installation, qualification and start up of comprehensive turnkey projects for pharma, veterinary and biotech industries according to the international regulations	
Services >	<ul style="list-style-type: none"> • Turnkey projects • Engineering Services • Project management • GMP Services • Critical facilities for pharmaceutical and biotech plants, biosafety facilities, Biobanks and R+D centers: <ul style="list-style-type: none"> • Clean room technology (Architecture, Air treatment and associated equipment), • Process (generation, storage and distribution of PW/WFI/PS, CIP/SIP, Process installations, waste treatment systems) • After Sales Service 	
Contact >	tel.: +34 91 371 79 70 / 93 544 29 10 http://www.tpro.es	Xavier Serra tprom@tpro.es



Tetra Therapeutics, S.L.

Contact >	tel.: +34 928457305 http://www.tetrath.com/	A. Carmelo González Rodríguez acgles@tetratx.com
---------------------	--	---



THROMBOTARGETS EUROPE

Thrombotargets Europe S.L.

Products >

Pipeline (13 products): Antihemorrhagic Program: TT-103MH, TT-111, TT-112, TT-125, TT-126. Anticoagulant Program: TT-105, TT-120 TT-123, TT-124 Antiplatelet Program: TT-113, TT-114, TT-115. Fibrinolytic Program: TT-116.
Technological Platforms: BioplatformScreen (ultra HTS), Recombinant Nanotransporters (NTR) (vehicles for therapeutic agents). Genetic Therapy (NTR containing genetic material)

Interest areas >

Our areas of interest are Pharmaceutical Development and HTS
Until that moment we have made alliances with: 6 Spanish Public Centers, 4 of which Universities. 3 International Public Centers - 2 in the USA and 1 in Brazil. 7 Spanish Private Companies. 3 International Private Companies - Russian, Dutch and North American

Contact >

tel.: +34 93 446 30 16

<http://www.thrombotargets.com>

Dr. Ignasi Miquel

ignasimiquel@thrombotargets.com



Valentia Biopharma

Mission >

Biotechnology Company focused on the Development of New Drosophila models of Genetic Human Diseases, and Drug Discovery using Automated in vivo Screening Technologies in Drosophila melanogaster models

Services >

Know-how and Biotechnology on the custom-made Design of Human diseases in Drosophila ;Drug Screenings on in vivo and in vitro Drosophila models; Bio-safety evaluation of chemicals for the European REACH regulation; Evaluation of Healthy Properties in nutritional products.

Interest areas >

ValentiaBP is strongly interested in setting up collaborations with Bio-Pharma for the Development of Screening Platforms based on Drosophila possible models; Become and active participant of Networks Institutions interested on Rare Diseases (RD) Research and; Establish Collaborations towards offering a consolidated joint portfolio of analytical tests for the European REACH regulation.

Contact >

tel.: +34 963543842

<http://www.valentibiopharma.com/>

José R. Tormo

jrtormo@valentibiopharma.com



VidaCord S.L.

Mission > To process and criopreserve the cord blood that parents entrust VidaCord. To offer their children in the future the possibility to use these cells or their derivatives to treat certain diseases.

Services > Obtaining, processing and criopreserving stem cells from blood cord

Interest areas > Cell Therapy. Regenerative Medicine

Contact > tel.: +34 91 702 68 79
http://www.vidacord.es

Mónica López Barahona
mlbarahona@vidacord.es



Vircell, S.L.

Mission > To produce quality reagents and to develop innovating products that imply significant advances

Products > Cell Culture: Cell lines, monoclonal antibodies, means of transporting virus. IFI: Immuno-fluorescence kits (single test and multitest). Brucellacapt: Diagnosis of Brucellosis. ELISA: Kits for the detection of specific antibodies. Controls of DNA/RNA: controls of PCR freeze-dried for an extensive range of infectious agents.

Contact > tel.: +34 958 441264
http://www.vircell.com

Almudena Rojas
arojas@vircell.com



Business Members



Vita Aidelos

Mission > VITA AIDELOS was set up with the objective of creating a positive attitude towards Biotechnology while maintaining scientific rigour. We aim at bridging the gap between the scientific community and society. We collaborate with foundations, museums and scientific sites. We spread scientific advances made in the field of Biotechnology and help society understand science by encouraging critical analysis

Products > Patents, know-how. Practice Kits in Biotechnology: Molecular Biology and Microbial Biotechnology. Multimedia Products. Services: Spreading and qualification in Biotechnology Practical consultancy. Taking part in events and activities aimed at spreading Biosciences.

Interest areas > Commercialization agreements. Taking part in R & D & I projects. Projects aimed at spreading science.

Contact >	tel.: +34 944 069 689 http://www.vita-aidelos.com/	Melania Rosique info@vita-aidelos.com
---------------------	--	---



Vivacell Biotechnology España, S.L.

Mission > VIVACELL BIOTECHNOLOGY ESPAÑA S.L. is a company focussed in Biomedicine and Pharmaceutical Chemistry that investigates in new medical products derived from medicinal plants. The activities of the company are concentrated in the preclinical phase of drug discovery. We have developed our own platforms of primary screening for plant extracts.

Products > Vivacell owns a large collection of plant-derived extracts biologically tested and a library of natural compounds. We have developed CDE-001, an standardised phytoextract with application in colon cancer and inflammatory bowel disease. In addition the company provides specialised in vitro and in vivo models for testing and developing pharmaceutical, nutraceutical and phytopharmaceutical compounds.

Contact >	tel.: +34 957290666 (637774192) http://www.vivacellspain.com	Dra. M.Luz Bellido Cabello de Alba m.bellido@vivacellspain.com
---------------------	--	--



Vivia Biotech

Mission >	Vivia Biotech is dedicated to the research of new indications for existing drugs ("reprofiling") in less common diseases (commonly known as "rare diseases"), in the most simple and direct way, but that had not been possible until now: analyzing by means of a pioneer proprietary technology ("ExviTech") the effect of thousands of existing drugs directly on a patient's standard biological sample while it is still fresh (24/48 hours).	
Products >	Vivia Biotech Centers its operations on the following areas of research. Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome): More than 100.000 potential new treatments will be evaluated during the next 1.5 years directly in patient samples. Combinatorial Cytomic Biomarkers. Development of cytomic biomarkers of chronic stress and depression on clinically characterized human samples.	
Interest areas >	Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome). Chronic Stress and Depression.	
Contact >	tel.: +34 952278916 http://www.viviabiotech.com	Juan Ballesteros / Isabel Pulido jballesteros@viviabiotech.com ipulido@viviabiotech.com



Vivotecnia Research S.L.

Mission >	Vivotecnia performs pre-clinical research on a contract basis. We offer reliable high quality investigation for the cosmetic, pharma and biotech industry.	
Services >	We offer solutions to research and development projects. We can perform a wide range of efficacy and toxicity studies. We are certified to work under GLP standards and can work with rodents, non rodents and dogs as required by FDA, EMEA and the rest of agencies around the world.	
Interest areas >	Activity, efficacy and toxicity studies in in vitro and in vivo models. Managing services for animal facilities and animal models. Animal facility services and rooms to rent	
Contact >	tel.: +34 91 728 07 15 http://www.vivotecnia.com	Antonio Vila Coro vilacoro@vivotecnia.com



Zeltia

Mission > Zeltia is an outstanding reference in the improvement of well-being through the fight against cancer, nervous system degenerative diseases and other diseases. We have therefore taken up the challenge of pre-empting the future, and this is only possible through constant innovation, with an R&D policy that has positioned us as one of the top eight Spanish companies in R&D investment.
The companies comprising the Group: Pharmamar S.A, Neuropharma S.A, Genómica S.A.U, Xylazel S.A and Zelnova S.A

Services > The discovery and development of drugs of marine origin, news, scientific publications

Interest areas > Zeltia since its beginnings has collaborated and continues collaborating actively with academics and public centers, with same and large businesses of the sector biopharmaceutical and of the chemical, so much national as international sector.

Contact >	tel.: +34 91 444 45 00 http://www.zeltia.com/	Carmen Eibe ceibe@zeltia.com
---------------------	---	---



ZF Biolabs, S.L.

Mission > We are specialized in the use of the Zebrafish (Danio rerio) as an animal model for biomedical and toxicological research.

Products > Developmental toxicity assay, acute toxicity assay, organ-specific toxicity assay, gene expression analysis services (RT-PCR), gene knock-down phenotyping.
Supply of zebrafish embryo and larvae, custom design systems for maintenance and breeding, inducing spawning technology, feed for adult and fry

Interest areas > Toxicity, animal models for human diseases, functional genomic studies, screening of compounds, contract research organization.

Contact >	tel.: +34 918049020 http://www.zfbiolabs.com	Joaquín Guinea López jguinea@zfbiolabs.com
---------------------	--	--

● Red biotechnology

● Green biotechnology

● Institutions



Association of Bioenterprises of Valencian Community Region

Mission > Bioval is a meeting platform for the biotechnological sector in Valencian Community region. Our objective is to promote and support the growth and cooperation of the biotechnological sector in our region. Bioval gathers private companies, research centres, universities, hospitals and other organizations where R+D activities are related to biotechnology.

Services > Information to their members, promotion of the biotechnical sector of the Valencian Community, promotion of the associate entities, promotion of this sector by means of an active presence in the media, trade exhibitions and different forums, foment of the innovation in the sector, impulse to technological transfer, representation of the interests of this sector before Civil Services.

Contact > tel.: +34 902 88 99 90
http://www.bioval.org

María Eugenia Hernández de Pablo
info@bioval.org



Aula Dei Foundation Science and Technology Park

Mission > To connect research centres and the companies. To support and encourage the companies within the agricultural and environmental sector to look for scientific and technological solutions. To transfer the results of the research centres linked to the Park to the production fabric. To spread the researchers' work to enhance its visibility. To arrange and promote the existing technology offer. To detect and give solution to the new technologies' needs. To encourage the creation and consolidation of innovative companies within the sector.

Products > Management of R + D + i contracts between companies and research centres. Advice regarding R & D projects. Business incubator. Innovation and Creation of new technology based firms Programme. Spin off Programme. Cooperation networks for knowledge and technology transference. Transferring and putting the technology on the market. Regional, National and International Financing of R + D + i projects. Training: specialised postgraduate and advanced courses for professionals.

Interest areas > Animal Health and Production. Environmental Technology. Forest Resources. Freshwater Resources and irrigation technology. Agricultural Economy. Vegetal health and Nutrition. Food quality and security technology. Biotechnology. Genetic Improvement. Agrifood production and container. Bio-mass. Wine technology

Contact > tel.: +34 976716976
http://www.pctad.com

Susana Martínez Hernández
smartinez@aragon.es



BioBasque, the Basque BioRegion

Mission >	To develop a new business sector related to life sciences, contributing to diversify the current industrial tissue and to maintain competitiveness in an international context.	
Products >	BioBasque is represented by the BioBasque Agency, a one-stop location for biosciences in the Basque Country, and the instrument created to implement the strategy and to co-ordinate the relevant stakeholders.	
Interest areas >	BioBasque is interested in establishing contacts with equivalent organisations, and other type of entities, that contribute to support the growth of the biocluster. It is equally interested in contacting companies wishing to establish operations in southern Europe.	
Contact >	tel.: +34 946 555 155 http://www.biobasque.org	Dr. María Aguirre biobasque@spri.es



Bioregió de Catalunya (BIOCAT)

Mission >	Biocat is the Catalonia biocluster organization with the aim to promote biotechnology and biomedicine in Catalonia. It is fostered by the Government of Catalonia and it is participated by companies and public research institutions	
Services >	Our main goals are: Facilitate networking among the different stakeholders. Foster biotechnology as a key economic driver for the country. Promote Catalonia biotechnology at the world stage. Inform and contribute to a better understanding and perception of biotechnology	
Contact >	tel.: +34 93 310 33 30 http://www.biocat.cat	Montse Daban mdaban@biocat.cat



Cartif Foundation - Foods and Chemicals Division - Biotechnology Laboratory



Mission >	The target of the Biotechnology Laboratory of CARTIF Foundation is to incorporate the biotechnology into the companies to increase the innovation in their activities. The main objective consists of the application of biotechnological tools in the agrofood sector in order to develop new production processes as well as to support the existing ones.	
Services >	Projects and services in R&D activities: Molecular tools implementation to solve the agro-food sector needs: trazability, food frauds, species identification and guarantee of origins. GMOs and pathogens detection (PCR-RT) as an answer to safety's problems in food, feed and agriculture feedstock. Biotechnological processes to upgrade the agro-industrial residues and to obtain new products.	
Interest areas >	New molecular tools development. Biocatalysis and enzymatic technologies. Immobilization techniques. Development of submerged and solid state fermentation systems.	
Contact >	tel.: +34 983 548818 http://www.cartif.es	Dra. M ^a Cristina Ramírez de Lara criram@cartif.es



Centro Nacional de Investigaciones Oncológicas, CNIO (The National Oncological Research Centre)



Mission >	Basic and applied research under an integrated approach, fostering the interaction of basic research with of molecular diagnostics programmes and of the discovery of new drugs, all supported by a solid equipment and technical services infrastructure.	
Services >	Undertaking research to enable the new, more efficient diagnosis and treatment methods to be obtained for oncological diseases. The transfer of scientific knowledge into clinical practice, so that scientific progress has an effect on our healthcare system as early as possible, and thus on patient welfare. The transfer of technology developed in the CNIO to innovating companies. To set up a new and more effective management system in the European scientific environment	
Contact >	tel.: +34 91 224 69 00 http://www.cnio.es	José Ignacio Fernández Vera vera@cnio.es



CIBER-BBN

Mission >	To increase research capabilities of the component groups (sharing resources, coordination and promotion of synergies). To enhance greater and better use of advanced technologies in the National Health System. To improve the technological level of national industry in this field. To favour the emergence of specialists with a high level of training in health technologies. To increase the presence of Spain in decision-making forums and international research networks in this field.	
Products >	Intelligent platform for a drug-free prevention of diabetes mellitus and cardiometabolic risk. Multimodal biomedical information integration toolkit, biomodeling and biosimulation techniques. Development of new concepts of scaffoldings and cell cultures for regenerative medicine, with applications in the vascular system, abdominal hernias. ... Enzyme replacement therapy in Fabry's disease. Obtaining biosensors for identifying pathogenic microorganisms with diagnostic uses. Development of molecular imaging strategies and of in vivo animal model phenotypes of human pathologies. Translational extension to patients	
Interest areas >	BIOENGINEERING AND BIOMEDICAL IMAGING: Multimodal diagnosis. Intelligent devices. BIOMATERIALS AND TISSUE ENGINEERING: Regenerative medicine (Scaffold-based Tissue Engineering; Cell therapy; Cell biophysics). Endoprostheses and implants. NANOMEDICINE: Molecular diagnosis and biosensors. Therapeutic nanoconjugates and drug delivery systems.	
Contact >	tel.: +34 976 51 23 68 http://www.ciber-bbn.es	Gonzalo Vicente Lacambra gvicente@ciber-bbn.es



CNTA - National Centre for Technology and Food Safety

Mission >	CNTA contributes to the development of the agri-food industry, providing enhanced technological services through Quality and Innovation under the principle of food safety. This goal is accomplished by providing the agri-food sector with services and technical support to improve their and competitiveness and innovation capacity in order to produce safer and healthier foods.	
Products >	Analytical control for processes and product improvement. Assistance in the implementation Food Safety and Quality Systems (FSQS). FSQS monitoring and assurance. Process Audits. Specialised training of technical/managing personnel. Development of R&D&I projects both individually and in collaboration with Industries, Universities and other Research Organisations, etc. Technological Consulting	
Interest areas >	Starter culture development (novel processes, improved performance, novel starters...). Development and assessment of novel Probiotics. Development of natural functional additives through clean technologies (biotechnology, bacteria, yeasts...). Development and assessment of functional foods. Cell Models, animal, nutrigenomics.	
Contact >	tel.: +34 948 670 159 http://www.cnta.es	Carlos González Navarro cgonavarro@cnta.es



Consejo Superior de Investigaciones Científicas, CSIC (The Higher Council for Scientific Research)

- Mission >** A public research body, under the auspices of the Spanish Ministry of Science and Technology, that provides research capacity and human resources and materials in the development of new scientific knowledge and the transformation of these into processes and products of social and economic interest.
- Services >** To draw up and execute scientific and technological research projects. To draw up and execute collaboration contracts and agreements with companies and with other social agents. To contribute to the analysis and selection of future scientific and technological aims and to advise public administrations on research and technological innovation matters. To foster progress in basic and applied research. To collaborate with the Regional Governments in subscribed research activities. To collaborate with the universities in research and higher education activities. To develop training programmes for researchers and technicians working in the field of science and technology. To collaborate with the National R&D Plan in advisory and management tasks commissioned and with the Regional Governments who request this in the undertaking of their science policies.
- Interest areas >** Projects in all the biotechnology and biomedicine areas and at the interface between biotechnology and organic chemistry, analytical chemistry, food technology, applied physics, etc. Collaboration with universities, technological centres, industries, etc. to enhance the flow that transforms basic science into social well-being.
- Contact >**
- | | |
|---|---|
| tel.: +34 91 585 53 01
http://www.csic.es | Prof. José M. Guisán Seijas
ott@csic.es |
|---|---|



Fundación Antama

- Mission >** To increase awareness about biotechnology and its applications in agriculture, the environment and food products.
- Services >** Communication, the organisation of events relating to biotechnology, cabinet for journalist consultations.
- Contact >**
- | | |
|---|--|
| tel.: +34 91 638 98 13
http://www.antama.es | Elena Fernández Guiral /
Alfredo López Zamora
fguiral@fundacion-antama.org |
|---|--|



Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía



Mission > Fundación MEDINA is a non-profit public-private partnership between Merck Sharp and Dohme de España S.A., the Junta de Andalucía and the University of Granada, to discover innovative compounds and therapies for unmet medical needs.

Products > New leads from microbial natural products collections in therapeutic areas identified as top priority by the national and regional Spanish Health Systems. Highly automated screening platform: evaluation of potential cardiovascular toxicities and adverse drug metabolism effects (ADME/TOX) of drug candidates in development. Ion channels assays (hERG, Cav1.2, Nav1.5). Drug metabolism assays (CYP inhibition and induction). Off-target interactions (neurotransmitter receptors, PPARs)

Interest areas > Discovery of novel therapeutics from microbial natural products collections in: infectious diseases (including tuberculosis and parasitic diseases), oncology, immunoregulation and rare diseases. Study of potential cardiovascular and neuronal safety risks, and drug-drug interactions of new leads in early stages of the drug-discovery process.

Contact > tel.: +34 958 993 965
<http://www.medinaandalucia.es> Olga Genilloud
olga.genilloud@medinaandalucia.es



Fundación Parque Científico de Madrid (PCM)



Mission > To foster scientific research

Services > Business Development: Support for entrepreneurs, Business Creation, Business Incubator, Bioincubator, Access to financing, scientific and university environment. Scientific Services: Genomics, Proteomics, Micro-analysis of materials, Bio-IT, Biotransformations, Animal Health Care.

Interest areas > The creation of companies with a technological base. Science services to biotech companies. Large scientific facilities. Technical assistance for the creation and management of science and technology parks.

Contact > tel.: +34 91 497 24 00
<http://www.fpcm.es> Antonio R. Díaz
parque.cientifico@pcm.uam.es



Gaiker

- Mission >** Gaiker is an innovating centre in technologies relating to plastic materials and composites, the environment, recycling and the evaluation and industrial biotechnology available to companies.
- Services >** Our range of products and services includes the undertaking of R&D projects, technological advisory services and assays and the certification of materials and products. This is complemented by the training we deliver, together with the organisation of communication activities and our technological documentation and surveillance services.
- Interest areas >** Gaiker's field of activity is the rendering of Technological Services and Innovation to companies, contributing to their technological development and their competitiveness through the generation, capturing, adaptation and transfer of innovating technologies in industrial biotechnology, plastics and their composites, the treatment and recuperation of contaminated waters and land, as well as industrial waste, recycling, reuse and revaluing of mass consumption waste.
- Contact >**
- | | |
|--|--|
| tel.: +34 946 002 323
http://www.gaiker.es | José María Goenaga
mark@gaiker.es |
|--|--|

Genoma España



Genoma España

- Mission >** Promote the creation of value from knowledge in strategic areas of the National R&D&I Plan,, especially in biotechnology, through technology transfer and training with the goal of improving the health and quality of life of citizens and the competitiveness of businesses, while establishing the framework for public-private partnerships.
- Services >** Our main goals are: Promote the active support and coordination of research carried out in Spain. Make better use of research resources and results by promoting technology transfer and supporting the creation of technology-based companies. Undertake tasks of technology watch, prospective and strategic analysis. Help in the internationalization and in the promotion of the Spanish biotechnology sector. Bring biotechnology closer to society.
- Contact >**
- | | |
|--|---|
| tel.: +34 914491250
http://www.gen-es.org | Belén Gilarranz
belen.gilarranz@gen-es.org |
|--|---|



Granada Health Sciences Technological Park (PTS Granada)



Mission > PTS Granada is a model for the transfer of basic clinical Research and Technology in the field of health and biomedicine which contributes to economic development via: The promotion of interdisciplinary research in biomedicine at an international level. The protection and transfer of knowledge. The consolidation of health sciences business framework based on technology and aimed at clinical practice. Being a centre of excellence for healthcare.

Services > RESEARCH SERVICES: Library, Cell Culture, DNA Sequencing, Genomics and Proteomics, Oligonucleotide Synthesis. SERVICES OF TECHNOLOGICAL INNOVATION: Funding of the I+D+i, Transfer of Technology, Industrial Property, Technological Alertness MANAGERIAL SERVICES: Services of EIBTs's creation, Services of incubation, Services of managerial development. GENERAL SERVICES: Security, Restaurant, Advisory and Consultation, Marketing and Advertising, Hotels, Healthcare Services, Business Associations, University of Granada, Bioincubator, Technological Innovation Network (RETA), Patents Centre (CITPIA), Innovation Centre, Creation of technology-based companies, Technological trampoline network (CESEAND, RTT), Business Development Support Centre (CADE)

Interest areas > Biotechnology and Human Health

Contact >	tel.: +34 958 53 50 50 http://www.ptsgranada.com	Jesús Quero Molina jquero@ptsgranada.com
---------------------	---	--



Inbiomed Foundation



Mission > Development of new products and medicines for cellular therapy. Development of genomic, proteomic and gene silencing technology in stem cells. Identification, characterization and growth of adult stem cells.

Services > Inbiomed offers research services for companies and investigators based on the use of stem cells related with research programs being undertaken in Inbiomed. Inbiobank: Human stem cell bank. Inbiopharma: Pharmaceutical laboratory. Technology Services: Contract research

Contact >	tel.: +34 943 30 90 64 http://www.inbiomed.org	Jose Manuel Franco inbiomed@inbiomed.org
---------------------	---	--



Instituto de Salud Carlos III



Mission > A public research body belonging to the Spanish Ministry of Health and Consumption, whose mission is to foster, develop and render technical scientific services in the field of human health care.

Services > Research into the different aspects relating to the application of genetic knowledge in diagnosis, therapy, the development of new drugs and epidemiology. The development of innovation in telematics, bio-IT, genomics and proteomics and other new technologies applied to health care. The conservation of international standards and the preparation and conservation of national standards. Awarding aid and subsidies for biomedical research. Drawing up reports about healthcare technologies and services aimed at consolidating decision-making at the different levels of the National Healthcare System.

Interest areas > Molecular Diagnosis. Telematics and Bio-IT. Proteomics and genomics. Healthcare technologies

Contact >	tel.: +34 918 222 000 http://www.isciii.es	Julia Medrano Chivite otri@isciii.es
---------------------	--	---



Industria, Innovación
y Empleo

La Rioja Government. Directorate-General for Innovation



Mission > R+D and Innovation Policies Design. Communication of the relevance of the R+D and Innovation issues. Regional coordination of those activities. Push up of the technology transfer. Facilitate the growing up of new innovative companies. Enlarge the research activity in La Rioja. Be in the European R+D and Innovation Network. Focus the local companies to the new technologies to improve their competitiveness

Services > New Third R+D and Innovation Regional Plan 2.008-2.011. New Regional Law for R+D and Innovation. Technology Surveillance and Prospective. Support our companies to participate in R+D and Innovation projects. Develop activities to transfer the biotechnological solutions to traditional companies. Helping companies to reach funds for biotechnological projects. Coordination of the Technologies Centres in La Rioja. Communicate to a public of all ages the relevance of the biotechnology

Interest areas > All related to the above mentioned objectives.

Contact >	tel.: +34 941 291 684 http://www.larioja.org	Javier Ureña Larragán dg.innovacion@larioja.org
---------------------	--	---



NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario



Mission >	Neiker is a Technological Center whose mission is performing research in the field of agricultural, animal, forestry and environmental sciences, being life sciences and biotechnology the base for all the previous research, contributing and collaborating to the development of the enterprise network of the former sectors.	
Services >	R+D+i projects. Analytical and advising services (E+C). Technological services, assistance and technical advising, education and training, technological alert and prospective. Technology transfer and support to the entrepreneurship.	
Contact >	tel.: +34 94 4034300 http://www.neiker.net	Susana Hormilla shormilla@neiker.net



Parc Científic de Barcelona (Barcelona Science Park)



Mission >	The Parc Científic de Barcelona (PCB) is a pioneering innovation system created 10 years ago by the University of Barcelona. The mission of the PCB is to boost quality research, to foster knowledge and technology transfer and to facilitate the creation of new, technology-based companies.	
Services >	It houses over 46 companies, three large research centers and the PCB-Santander Bioincubator, which undertake their activity in the emerging areas of chemical, pharmaceutical and biotechnology research as well as nano-bioengineering. The PCB's hosts have access to a large technology offer (www.pcb.ub.es/servicios), including: Technology Platforms. Scientific and Technical Services SCT-UB. Scientific Services-PCB	
Interest areas >	The PCB collaborates and seeks alliances with researchers, entrepreneurs, institutions and companies interested in making contributions to the fields of biomedicine, nano-bioengineering, biotechnology, agro-food and other related areas. They may devote their efforts to basic research, to product development or to the creation of technology-based innovative companies.	
Contact >	tel.: +34 93 402 90 60 http://www.pcb.ub.es	Sonia Martínez Arca smartinez@pcb.ub.es



Parc de Recerca UAB. Oficina de innovación, traducción y creación de empresas

Mission >	To foster the entrepreneurial spirit within the UAB. To foster the creation of an entrepreneurial centre in order to attract innovating projects from entrepreneurs within the sphere of the UAB in their most embryonic stages and to support them during their creation period until they become competitive companies going on to form part of Catalonia's business fabric.	
Services >	To support the execution of business plans from UAB entrepreneurs. Personal accompaniment and coaching. Specific training in the area of entrepreneurship. Seeking financing for business initiatives. To support project viability during the established creation period. Consolidation of human capital and setting up of strategic alliances. Management and co-ordination of UAB company incubator. Internationalisation and networking	
Contact >	tel.: +34 935814235 http://www.uab.es	Sònia González sgonzalezg@uab.cat



Universidad de Navarra

Mission >	Higher education, basic and applied research and specialized medical attention.	
Contact >	tel.: +34 948425 600 http://www.unav.es	José Manuel Zumaquero/ María Font jmzumaquero@unav.es



Veterindustria

Mission >	To defend the collective interests of the associated companies that manufacture and/or commercialise the following products and services in Spain: Veterinary medicines, animal healthcare and nutritional products and additives for animal nutrition, through its different co-ordination, advisory and communication services, to thus promote all the aspects of the Animal Healthcare and Nutrition Industry, benefiting both the sector and society in general.	
Contact >	tel.: +34 91 369 21 34 http://www.veterindustria.com	Santiago de Andrés veterindustria@veterindustria.com



5th International Meeting on Biotechnology

September 29 - October 1 2010

Pamplona – Spain

About



BIOSPAIN is the top biotechnology event in Spain, organized by **ASEBIO** – the Spanish Bioindustry Association and **SODENA** – Navarre's government development agency. Since the first edition, launched back in the year 2003, it has become one of the leading biotechnology events in Europe.

BIOSPAIN 2010 will feature a trade exhibition, partnering event, investment forum, scientific congress, seminars and career fair with a well-balanced mixture of local and international private companies, universities, overseas clusters, research institutes and governmental bodies.

CONTACT

Navarra Consultores de Comunicación S.L.
C/ Navas de Tolosa, 19 -2º Dcha
31002 Pamplona. Navarra. Spain

Phone: +34 948 22 39 82


Fax: +34 948 22 34 20

E-mail: maria@nccsl.com
dfernandez@asebio.com


www.biospain2010.org

Profile of participants (based on Biospain 2008)


By Industry



By Position



By Region



> Apply to reserve your exhibition space now!





GOBIERNO
DE ESPAÑA

MINISTERIO
DE INDUSTRIA, TURISMO
Y COMERCIO

ICEX

INSTITUTO
ESPAÑOL
DE COMERCIO
EXTERIOR

asebio